View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Jan. 19, 2018	Jun. 30, 2017
Document Document And Entity Information [Abstract]
Entity Registrant Name	INTUITIVE SURGICAL INC
Entity Central Index Key	0001035267
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	ISRG
Amendment Flag	false
Entity Common Stock, Shares Outstanding		112,298,504
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 34,385,417,181

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 648.2	$ 1,036.6
Short-term investments	1,312.4	1,518.0
Accounts receivable, net of allowances of $4.6 and $1.9 as of December 31, 2017, and 2016, respectively	511.9	430.2
Inventory	241.2	182.3
Prepaids and other current assets	97.2	83.3
Total current assets	2,810.9	3,250.4
Property, plant, and equipment, net	613.1	458.4
Long-term investments	1,885.9	2,283.3
Deferred tax assets	87.3	150.9
Intangible and other assets, net	159.7	142.8
Goodwill	201.1	201.1
Total assets	5,758.0	6,486.9
Current liabilities:
Accounts payable	82.5	68.5
Accrued compensation and employee benefits	167.6	136.4
Deferred revenue	284.5	240.6
Other accrued liabilities	169.5	151.0
Total current liabilities	704.1	596.5
Other long-term liabilities	327.1	112.6
Total liabilities	1,031.2	709.1
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; no shares issued and outstanding as of December 31, 2017, and 2016	0.0	0.0
Common stock, 300.0 shares authorized, $0.001 par value, 112.3 shares and 116.4 shares issued and outstanding as of December 31, 2017, and 2016, respectively	0.1	0.0
Additional paid-in capital	4,679.2	4,211.8
Retained earnings	61.4	1,574.9
Accumulated other comprehensive loss	(15.5)	(8.9)
Total Intuitive Surgical, Inc. stockholders’ equity	4,725.2	5,777.8
Noncontrolling interest in joint venture	1.6	0.0
Total stockholders’ equity	4,726.8	5,777.8
Total liabilities and stockholders’ equity	$ 5,758.0	$ 6,486.9

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance	$ 4.6	$ 1.9
Preferred stock, shares authorized	2,500,000.0	2,500,000.0
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	300,000,000.0	300,000,000.0
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, shares issued	112,300,000	116,400,000
Common stock, shares outstanding	112,300,000	116,400,000

Consolidated Statements Of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Product	$ 2,547.1	$ 2,187.4	$ 1,919.6
Service	581.8	517.0	464.8
Total revenue	3,128.9	2,704.4	2,384.4
Cost of revenue:
Product	754.9	663.3	647.2
Service	179.9	151.0	159.3
Total cost of revenue	934.8	814.3	806.5
Gross profit	2,194.1	1,890.1	1,577.9
Operating expenses:
Selling, general and administrative	810.9	705.3	640.5
Research and development	328.6	239.6	197.4
Total operating expenses	1,139.5	944.9	837.9
Income from operations	1,054.6	945.2	740.0
Interest and other income, net	41.9	35.6	18.5
Income before taxes	1,096.5	980.8	758.5
Income tax expense	436.5	244.9	169.7
Net income	$ 660.0	$ 735.9	$ 588.8
Net income per share:
Basic (usd per share)	$ 5.91	$ 6.40	$ 5.29
Diluted (usd per share)	$ 5.67	$ 6.24	$ 5.18
Shares used in computing net income per share:
Basic (shares)	111.7	114.9	111.3
Diluted (shares)	116.3	117.9	113.7

Consolidated Statements Of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 660.0	$ 735.9	$ 588.8
Other comprehensive income (loss):
Change in foreign currency translation gains (losses)	3.6	2.0	(1.2)
Available-for-sale investments:
Change in unrealized losses, net of tax	(2.7)	(4.6)	(3.2)
Less: Reclassification adjustment for net gains (losses) on investments recognized during the year, net of tax	0.0	0.2	(0.8)
Net change, net of tax effect	(2.7)	(4.4)	(4.0)
Derivative instruments:
Change in unrealized gains (losses)	(8.6)	4.1	7.8
Less: Reclassification adjustment for gains (losses) on derivative instruments recognized during the year, net of tax	1.2	(0.6)	(7.4)
Net change, net of tax effect	(7.4)	3.5	0.4
Employee benefit plans:
Change in unrealized losses, net of tax	(0.3)	(0.7)	(0.4)
Less: Reclassification adjustment for gains on employee benefit plans recognized during the year, net of tax	0.2	0.2	0.8
Net change, net of tax effect	(0.1)	(0.5)	0.4
Other comprehensive gains (losses)	(6.6)	0.6	(4.4)
Total comprehensive income	$ 653.4	$ 736.5	$ 584.4

Consolidated Statements Of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Intuitive Surgical, Inc. Stockholders’ Equity	Non controlling Interest
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,379.4	$ 0.0	$ 2,896.8	$ 487.7	$ (5.1)	$ 3,379.4	$ 0.0
Beginning balances (shares) at Dec. 31, 2014		36.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options and under stock purchase plan (in shares)		1.2
Issuance of common stock through employee stock plans	361.1		361.1			361.1
Income tax benefit from employee stock plans	21.4		21.4			21.4
Shares withheld related to net share settlement of equity awards	(11.0)		(1.1)	(9.9)		(11.0)
Share-based compensation expense related to employee stock plans	167.9		167.9			167.9
Repurchase and retirement of common stock (in shares)		(0.4)
Repurchase and retirement of common stock	(183.7)		(16.3)	(167.4)		(183.7)
Net income	588.8			588.8		588.8
Other comprehensive loss	(4.4)				(4.4)	(4.4)
Ending balances (shares) at Dec. 31, 2015		37.4
Ending balance at Dec. 31, 2015					(9.5)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,319.5	$ 0.0	3,429.8	899.2	(9.5)	4,319.5	0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options and under stock purchase plan (in shares)		1.5
Issuance of common stock through employee stock plans	580.9		580.9			580.9
Income tax benefit from employee stock plans	29.8		29.8			29.8
Shares withheld related to net share settlement of equity awards	(24.0)		(2.2)	(21.8)		(24.0)
Share-based compensation expense related to employee stock plans	177.6		177.6			177.6
Repurchase and retirement of common stock (in shares)		(0.1)
Repurchase and retirement of common stock	(42.5)		(4.1)	(38.4)		(42.5)
Net income	735.9			735.9		735.9
Other comprehensive loss	$ 0.6				0.6	0.6
Ending balances (shares) at Dec. 31, 2016	116.4	38.8
Ending balance at Dec. 31, 2016	$ 5,777.8				(8.9)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,777.8	$ 0.0	4,211.8	1,574.9	(8.9)	5,777.8	0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Three-for-one stock split (shares)		77.6
Three-for-one stock split	0.0	$ 0.1	(0.1)
Proceeds from Noncontrolling Interests	2.0						2.0
Issuance of common stock upon exercise of options and under stock purchase plan (in shares)		3.4
Issuance of common stock through employee stock plans	415.5		415.5			415.5
Shares withheld related to net share settlement of equity awards (shares)		(0.2)
Shares withheld related to net share settlement of equity awards	(56.6)		(5.1)	(51.5)		(56.6)
Share-based compensation expense related to employee stock plans	209.1		209.1			209.1
Repurchase and retirement of common stock (in shares)		(7.3)
Repurchase and retirement of common stock	(2,274.0)		(152.0)	(2,122.0)		(2,274.0)
Net income	660.0			660.0		660.0
Other comprehensive loss	(6.6)				(6.6)	(6.6)
Loss in noncontrolling interest	$ (0.4)						(0.4)
Ending balances (shares) at Dec. 31, 2017	112.3	112.3
Ending balance at Dec. 31, 2017	$ 4,725.2				(15.5)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 4,726.8	$ 0.1	$ 4,679.2	$ 61.4	$ (15.5)	$ 4,725.2	$ 1.6

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net income	$ 660.0	$ 735.9	$ 588.8
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and loss on disposal of property, plant, and equipment, net	86.2	73.9	65.1
Amortization of intangible assets	12.9	18.2	24.4
Loss on investment, accretion of discounts, and amortization of premiums on investments, net	21.2	35.9	26.4
Deferred income taxes	62.9	18.7	4.6
Income tax benefits from employee stock plans	0.0	29.8	21.5
Share-based compensation expense	209.1	177.6	167.9
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	(81.7)	(35.9)	(79.2)
Inventory	(115.5)	(46.7)	(10.7)
Prepaids and other assets	(28.5)	(28.7)	(10.5)
Accounts payable	14.0	15.9	(11.3)
Accrued compensation and employee benefits	31.2	18.7	21.5
Deferred revenue	52.8	19.9	8.2
Other liabilities	219.3	53.8	(10.5)
Net cash provided by operating activities (1)	1,143.9	1,087.0	806.2
Investing activities:
Purchase of investments	(1,995.0)	(2,585.5)	(1,827.4)
Proceeds from sales of investments	1,861.3	389.9	233.1
Proceeds from maturities of investments	703.1	970.1	825.8
Purchase of property, plant and equipment, and intellectual property	(190.7)	(53.9)	(81.0)
Net cash provided by (used in) investing activities	378.7	(1,279.4)	(849.5)
Financing activities:
Proceeds from issuance of common stock relating to employee stock plans	415.5	580.9	361.1
Taxes paid related to net share settlement of equity awards	(56.6)	(24.0)	(11.0)
Repurchase and retirement of common stock	(2,274.0)	(42.5)	(183.7)
Other financing activities	2.0	0.0	(7.3)
Net cash provided by (used in) financing activities (1)	(1,913.1)	514.4	159.1
Effect of exchange rate changes on cash and cash equivalents	2.1	0.0	(1.5)
Net increase (decrease) in cash and cash equivalents	(388.4)	322.0	114.3
Cash and cash equivalents, beginning of year	1,036.6	714.6	600.3
Cash and cash equivalents, end of year	$ 648.2	1,036.6	714.6
ASU No. 2016-09
Changes in operating assets and liabilities, net of effects of acquisition:
Net cash provided by operating activities (1)		44.1	34.3
Financing activities:
Net cash provided by (used in) financing activities (1)		$ (44.1)	$ (34.3)

Description of the Business	12 Months Ended
Description of the Business	Dec. 31, 2017
Accounting Policies [Abstract]
Description of the Business	DESCRIPTION OF THE BUSINESS Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci^® Surgical Systems and related instruments and accessories, which taken together, are advanced surgical systems that the Company considers an advanced generation of surgery. This advanced generation of surgery, which the Company calls da Vinci Surgery, combines the benefits of MIS for patients with the ease of use, precision and dexterity of open surgery. A da Vinci Surgical System consists of a surgeon’s console, a patient-side cart, and a high performance vision system. The da Vinci Surgical System translates a surgeon’s natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions, or ports. The da Vinci Surgical System is designed to provide its operating surgeons with intuitive control, range of motion, fine tissue manipulation capability, and 3-D HD vision while simultaneously allowing surgeons to work through the small ports enabled by MIS procedures.

Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its wholly- and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The Consolidated Financial Statements include the results and the balances of the Company's majority-owned joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The Company holds a controlling financial interest in the joint venture and the noncontrolling interest is reflected as a separate component of the consolidated stockholders’ equity. Noncontrolling interest in net income was inconsequential to the consolidated results for all periods presented and, therefore, has been included as a component of interest and other income, net in the consolidated statements of income.

Common Stock Split

Shares issued pursuant to the three-for-one stock split (the “Stock Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share, were distributed on October 5, 2017, to stockholders of record as of September 29, 2017. All share and per share information presented in the Consolidated Financial Statements have been retroactively adjusted to reflect the Stock Split.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult, and subjective judgments include the valuation and recognition of investments, the valuation of the revenue and allowance for sales returns and doubtful accounts, the estimation of hedging transactions, the valuation of inventory, the assessment of recoverability of intangible assets and their estimated useful lives, revenue recognition, the valuation and recognition of share-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, and legal contingencies estimates. Actual results could differ materially from these estimates.

Concentrations of Credit Risk and Other Risks and Uncertainties

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.

The Company’s accounts receivable are derived from net revenue to customers and distributors located throughout the world. The Company performs credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date. As of December 31, 2017, and 2016, 69% and 73%, respectively, of accounts receivable were from domestic customers. No single customer represented more than 10% of total revenue for the years ended December 31, 2017, 2016, and 2015.

During the years ended December 31, 2017, 2016, and 2015, domestic revenue accounted for 73%, 72%, and 71% of total revenue, respectively, while outside of the U.S. revenue accounted for 27%, 28%, and 29%, respectively, of total revenue for each of the years then ended.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity from date of purchase of 90 days or less to be cash equivalents.

Investments

Available-for-sale investments. The Company’s investments may consist of U.S. treasury and U.S. government agency securities, taxable and tax exempt municipal notes, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and money market funds. The Company has designated all investments as available-for-sale and, therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with original maturities greater than approximately three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.

Other-than-temporary impairment. All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary included the extent and length of time the investment's fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not the Company will be required to sell the security prior the expected recovery of the investment's amortized cost basis. No such charges were recorded during the years ended December 31, 2017, 2016, and 2015.

Fair Value Measurements

The Company measures the fair value of money market funds and certain U.S. treasury securities based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, and municipal notes. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.

Inventory

Inventory is stated at the lower of standard cost, which approximates actual costs, or net realizable value, on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company’s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions.

Property, Plant, and Equipment

Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets generally as follows:



	Useful Lives
Building	Up to 30 years
Building improvements	Up to 15 years
Leasehold improvements	Lesser of useful life or term of lease
Equipment and furniture	5 years
Operating lease assets	Greater of lease term or 1 to 5 years
Computer and office equipment	3 years
Enterprise-wide software	5 years
Purchased software	Lesser of 3 years or life of license

Depreciation expense for the years ended December 31, 2017, 2016, and 2015, was $82.1 million, $70.7 million, and $61.1 million, respectively.

Capitalized Software Costs for Internal Use

Internally developed software primarily includes enterprise-level business software that the Company customizes to meet its specific operational needs. The Company capitalized costs for internal use software of $22.4 million, $11.8 million, and $14.8 million during the years ended December 31, 2017, 2016, and 2015, respectively. Upon being placed in service, these costs are depreciated over an estimated useful life of up to 5 years.

Goodwill and Intangible Assets

Goodwill and intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net tangible and identifiable intangible assets. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of December 31, 2017, there has been no impairment of goodwill.

Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately 1 to 9 years.

Impairment of Long-lived Assets

The Company evaluates long-lived assets, which include amortizable intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sales of systems, instruments and accessories, and service revenue. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue is presented net of taxes collected from customers that are remitted to government authorities. The Company generally recognizes revenue at the following points in time:

•System sales. For systems, system components, or system accessories sold directly to end customers, revenue is recognized when acceptance occurs, which is deemed to have occurred upon customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized when title and risk of loss has transferred, which generally occurs at the time of shipment. Distributors do not have price protection rights and the Company’s system arrangements generally do not provide a right of return. The da Vinci Surgical Systems are delivered with a software component. However, because the software and non-software elements function together to deliver the system’s essential functionality, the Company's arrangements are excluded from being accounted for under software revenue recognition guidance.

•Instruments and accessories. Revenue from sales of instruments and accessories is generally recognized at the time of shipment. The Company allows its customers in the normal course of business to return unused products for a limited period of time subsequent to initial purchase and records an allowance against revenue recognized based on historical experience.

•Service. Service revenue is recognized ratably over the term of the service period. Revenue related to services performed on a time-and-materials basis is recognized when it is earned and billable.

The Company offers its customers the opportunity to trade in their older systems for credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered as separate deliverables in the arrangement for a system sale.

As part of a trade-in transaction, the customer receives a new generation system in exchange for its pre-owned system. The trade-in credit is negotiated at the time of the trade-in and is applied towards the purchase price of the new generation unit. Traded-in systems can be reconditioned and resold. The Company accounts for trade-ins consistent with the guidance in AICPA Technical Practice Aid 5100.01, Equipment Sales Net of Trade-Ins (“TPA 5100.01”). The Company applies the accounting guidance by crediting system revenue for the negotiated price of the new generation system, while the difference between (a) the trade-in allowance and (b) the net realizable value of the traded-in system less a normal profit margin is treated as a sales allowance. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. Traded-in units are reported as a component of inventory until reconditioned and resold, or otherwise disposed.

In addition, customers may also have the opportunity to upgrade their systems, for example, by adding a fourth arm to a three-arm system, adding a second surgeon console for use with the da Vinci Si, Xi, and X Surgical Systems, or by upgrading a da Vinci X Patient-Side Cart to an Xi Patient-Side Cart. Such upgrades are performed by completing component level upgrades at the customer’s site or by swapping out the component upgraded. Upgrade revenue is recognized when the component level upgrades have been completed and all other revenue recognition criteria have been met.

The Company's system sale arrangements contain multiple elements including a system(s), system accessories, instruments, accessories, and system service. A da Vinci Surgical Systems are comprised of three components; a Patient-Side Cart, Surgeon’s Console, and a Vision Cart. The Company generally delivers all of the elements, other than service, within days of entering into the system sale arrangement. da Vinci X and Xi Patient-Side Carts, Surgeon’s Consoles, and Vision Carts are also sold on a stand-alone basis, as are system accessories, instruments, accessories, and service. Each of these elements is a separate unit of accounting.

For multiple-element arrangements, revenue is allocated to each unit of accounting based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence of fair value (“VSOE”), then on third-party evidence of selling price (“TPE”) when VSOE does not exist, and then on management's best estimate of the selling price (“ESP”) when VSOE and TPE do not exist.

The Company’s system sales arrangements generally include a one-year period of free service and four additional years of service that are generally billed for separately on an annual basis at a contractually stated price. The revenue allocated to the free service period is deferred and recognized ratably over the free service period. Amounts billed for the additional years of service are recorded into deferred revenue when they are billed and recognized ratably over the service period. Deferred revenue, for the periods presented, was primarily comprised of contract consideration related to services not yet performed.

Because the Company has neither VSOE nor TPE for its systems, the allocation of revenue is based on ESP for the systems sold. The objective of ESP is to determine the price at which the Company would transact a sale, had the product been sold on a stand-alone basis. The Company determines ESP for its systems by considering multiple factors, including, but not limited to, features and functionality of the system, geographies, type of customer, and market conditions. The Company regularly reviews ESP and maintains internal controls over establishing and updating these estimates.

Leases

The Company enters into sales-type lease and operating lease arrangements with certain qualified customers to purchase or rent its systems. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative selling prices as prescribed by the Company's revenue recognition policy. Lease elements generally include a da Vinci Surgical System or system component, while non-lease elements generally include service, instruments and accessories. In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms: (1) whether title of the system transfers automatically or for a nominal fee at the end of the term of the lease, (2) whether the present value of the minimum lease payments are equal to or greater than 90% of the fair market value of the leased asset at the inception of the lease, (3) whether the lease term exceeds 75% of the economic life of the leased asset, and (4) whether there is an option to purchase the leased asset at a "bargain price" at the end of the lease term.

The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue from sales-type leases is presented as product revenue. Revenue from operating lease arrangements is recognized as earned over the lease term, which is generally on a straight-line basis and is presented as product revenue. Operating lease revenue for the years ended December 31, 2017, 2016, and 2015, was $25.9 million, $16.6 million, and $7.0 million, respectively.

Allowance for Sales Returns and Doubtful Accounts

The allowance for sales returns is based on the Company’s estimates of potential future product returns and other allowances related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company's products. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.

Share-Based Compensation

The Company accounts for share-based employee compensation plans using the fair value recognition and measurement provisions under U.S. GAAP. The Company’s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period.

Expected Term: The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time it will take for employees to exercise options still outstanding.

Expected Volatility: The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on at least one-year traded options on the Company’s common stock. The extent to which the Company relies on market-based volatility when valuing options, depend among other things, on the availability of traded options on the Company’s stock and the term of such options. Due to sufficient volume of the traded options, the Company used 100% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.

Risk-Free Interest Rate: The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.

The fair value of restricted stock units is determined based on the closing quoted price of the Company’s common stock on the day of the grant. See “Note 9. Share-Based Compensation,” for a detailed discussion of the Company’s stock plans and share-based compensation expense.

Computation of Net Income per Share

Basic net income per share is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share is computed using the weighted-average number of the Company’s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company's employee stock purchase plan.

U.S. GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.

Research and Development Expenses

Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development R&D licensing arrangements, costs of prototypes, salaries, benefits and other headcount related costs, contract and other outside service fees, and facilities and overhead costs.

Foreign Currency and Other Hedging Instruments

For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders’ equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.

The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company's derivative contracts are generally twelve months or shorter. The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.

The Company’s accounting policies for these instruments are based on whether the instruments are designated as hedge or non-hedge instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (“OCI”) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two month time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in fair value of such derivative instruments also are reflected in current earnings.

Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.

The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Segments

The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. As of December 31, 2017, and 2016, 88% and 86% of long-lived assets were in the United States. Revenue is attributed to a geographic region based on the location of the end customer.

Legal Contingencies

The Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company’s consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible, but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. The Company expenses legal fees as incurred.

When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company's business, financial condition, and results of operations or cash flows.

Recent Accounting Pronouncements Not Yet Adopted

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers, which sets forth a single, comprehensive revenue recognition model for all contracts with customers to improve comparability. Subsequently, the FASB has issued several standards related to ASU 2014-09 (collectively, the “New Revenue Standard”). The New Revenue Standard requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In addition, the New Revenue Standard requires expanded disclosures. This New Revenue Standard permits the use of either the retrospective or cumulative effect transition method when adopted. The New Revenue Standards becomes effective for the Company in the first quarter of fiscal year 2018.

The Company will adopt the New Revenue Standard in the first quarter of fiscal year 2018 using the full retrospective method to restate each prior reporting period presented in its Financial Statements. In preparation of adopting the New Revenue Standard, the Company has implemented additional internal controls and updated key system functionality to enable future preparation of financial information in accordance with the New Revenue Standard. The Company has also substantially completed its evaluation of the impact of the New Revenue Standard on its historical financial statements. Based on that evaluation, the Company has concluded that future billings related to future service included in its multi-year contracts should be part of the consideration allocated to all performance obligations under the New Revenue Standard. Under the current standard, future service billings are considered to be contingent revenue, and therefore, are not included in the consideration allocated. Accordingly, the amount of consideration allocated to the performance obligations identified in the Company’s system arrangements will be different under the New Revenue Standard than the amount allocated under the current standard. In general, this will result in an acceleration of the amount revenue recognized for system sales with multi-year service contracts.

The Company currently expects total revenue to increase by approximately $9 million and $2 million for fiscal 2017 and 2016, respectively. Because future service billings will be included in the contract consideration allocated to all performance obligations in system sales arrangements with multi-year service commitments, the Company currently expects that a greater amount of revenue will be allocated to the product related performance obligations under the New Revenue Standard. This is expected to result in a shift or reclassification of $9 million and $6 million from service to product revenue for fiscal year 2017 and 2016, respectively. In addition, contract acquisition costs, such as sales commissions paid in connection with system sales with multi-year service contracts, will be capitalized and amortized over the economic life of the contract under the New Revenue Standard. Under the current guidance, the Company expenses such costs when incurred. As a result, the Company currently expects that operating expenses will decrease by approximately $1 million and $2 million for fiscal years 2017 and 2016, respectively.

The New Revenue Standard is principle based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice, and guidance may evolve as companies and the accounting profession work to implement this new standard. While substantially complete, the Company is still in the process of finalizing its evaluation of the effect of the New Revenue Standard on the Company’s historical financial statements and disclosures. The Company will finalize its accounting assessment and quantitative impact of the adoption of the New Revenue Standard during the first quarter of fiscal year 2018. As the Company completes its evaluation of this new standard, new information may arise that could change the Company’s current understanding of the impact to revenue and expense recognized. Additionally, the Company will continue to monitor industry activities and any additional guidance provided by regulators, standards setters, or the accounting profession and adjust the Company’s assessment and implementation plans accordingly.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which amends the existing accounting standards for leases. The new standard requires lessees to record a right-of-use asset and a corresponding lease liability on the balance sheet (with the exception of short-term leases). The new standard also requires expanded disclosures regarding leasing arrangements. The new standard becomes effective for the Company in the first quarter of fiscal year 2019 and early adoption is permitted. The new standard is required to be adopted using the modified retrospective approach and requires application of the new standard at the beginning of the earliest comparative period presented. The Company generally does not lease equipment or other capital assets, but does lease some of its facilities. The Company’s customers finance purchases of systems and ancillary products, including directly with the Company. It is currently unknown whether the new standard will change customer buying patterns or behaviors. The Company is evaluating the effect that this new standard will have on its Financial Statements and related disclosures.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. Previously, the recognition of current and deferred income taxes associated with an intra-entity asset transfer was prohibited until an asset had been sold to a third party. This ASU will be effective for the Company in first quarter of 2018. This ASU is required to be adopted using the modified retrospective approach, with a cumulative catch-up adjustment to retained earnings in the period of adoption. Upon adoption, the Company will record deferred tax assets with an offset to opening retained earnings for amounts that entity had previously not recognized under existing guidance, but would be required to recognize under the new guidance. The Company currently expects that the adoption will result in an increase in deferred tax assets, with the corresponding cumulative effect adjustment recorded in retained earnings of approximately $390 million associated with an intra-entity transfer of certain intellectual property rights related to the Company’s non-U.S. business to its Swiss entity. The estimated adoption date impact may be materially different as a result of recording additional deferred taxes upon finalization of the assessment of global intangible low-taxed income (“GILTI”) and other aspects from additional guidance and interpretations by U.S. regulatory and standard-setting bodies related to the Tax Cuts and Jobs Act (“2017 Tax Act”).

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard will be effective for the Company in the first quarter of 2018. The Company does not expect a material impact upon the adoption of this ASU. Adoption of this ASU will not impact prior periods but may impact the accounting of future transactions.

Adopted Accounting Pronouncement

Beginning in fiscal year 2017, the Company adopted ASU No. 2016-09, Improvements to Employee Share-based Payment Accounting, which changes among other things, how the tax effects of share-based awards are recognized. ASU No. 2016-09 requires excess tax benefits and tax deficiencies to be recognized in the provision for income taxes as discrete items in the period when the awards vest or are settled, whereas previously such income tax effects were generally recorded as part of additional paid-in capital. The provision for income taxes for the year ended December 31, 2017, included excess tax benefits of $102.8 million that reduced the Company’s effective tax rate by 9.4 percentage points. The recognized excess tax benefits resulted from share-based compensation awards that vested or were settled during the year ended December 31, 2017. This ASU also eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities on the Company's Consolidated Statements of Cash Flows. The Company adopted this provision retrospectively by reclassifying $44.1 million and $34.3 million of excess tax benefits from financing activities to operating activities for the year ended December 31, 2016, and 2015, respectively. The Company also excluded the related tax benefits when applying the treasury stock method for computing diluted shares outstanding on a prospective basis as required by this ASU. In addition, the Company elected to continue its current practice of estimating expected forfeitures. The amount of excess tax benefits and deficiencies recognized in the provision for income taxes will fluctuate from period to period based on the price of the Company’s stock, the volume of share-based instruments settled or vested, and the value assigned to share-based instruments under U.S. GAAP.

Financial Instruments

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Financial Instruments

FINANCIAL INSTRUMENTS

Cash, Cash Equivalents, and Investments

The following tables summarize the Company’s cash and available-for-sale marketable securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents or short-term or long-term investments as of December 31, 2017, and 2016 (in millions):



										Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2017
Cash	$	197.7	$	—	$	—		$	197.7	$	197.7	$	—	$	—
Level 1:
Money market funds	445.0		—		—			445.0		445.0		—		—
U.S. treasuries	1,029.1		—		(4.7		)	1,024.4		5.5		396.2		622.7
Subtotal	1,474.1		—		(4.7		)	1,469.4		450.5		396.2		622.7
Level 2:
Commercial paper	38.4		—		—			38.4		—		38.4		—
Corporate securities	946.6		0.2		(4.4		)	942.4		—		403.9		538.5
U.S. government agencies	901.3		—		(4.4		)	896.9		—		311.7		585.2
Non-U.S. government securities	2.5		—		—			2.5		—		2.5		—
Municipal securities	301.1		—		(1.9		)	299.2		—		159.7		139.5
Subtotal	2,189.9		0.2		(10.7		)	2,179.4		—		916.2		1,263.2
Total assets measured at fair value	$	3,861.7	$	0.2	$	(15.4	)	$	3,846.5	$	648.2	$	1,312.4	$	1,885.9



										Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2016
Cash	$	227.7	$	—	$	—		$	227.7	$	227.7	$	—	$	—
Level 1:
Money market funds	612.4		—		—			612.4		612.4		—		—
U.S. treasuries	625.9		0.1		(2.0		)	624.0		157.9		168.4		297.7
Subtotal	1,238.3		0.1		(2.0		)	1,236.4		770.3		168.4		297.7
Level 2:
Commercial paper	139.6		—		—			139.6		31.1		108.5		—
Corporate securities	1,471.8		0.7		(5.0		)	1,467.5		2.9		555.4		909.2
U.S. government agencies	938.7		0.5		(2.9		)	936.3		—		342.7		593.6
Non-U.S. government securities	18.5		—		—			18.5		—		16.0		2.5
Municipal securities	815.4		—		(3.5		)	811.9		4.6		327.0		480.3
Subtotal	3,384.0		1.2		(11.4		)	3,373.8		38.6		1,349.6		1,985.6
Total assets measured at fair value	$	4,850.0	$	1.3	$	(13.4	)	$	4,837.9	$	1,036.6	$	1,518.0	$	2,283.3

There were no transfers between Level 1 and Level 2 measurements during the year ended December 31, 2017, and there were no changes in the valuation techniques used.

The following table summarizes the contractual maturities of the Company’s cash equivalents and available-for-sale investments (excluding cash and money market funds), at December 31, 2017 (in millions):



	Amortized Cost		Fair Value
Mature in less than one year	$	1,320.7	$	1,317.9
Mature in one to five years	1,898.3		1,885.9
Total	$	3,219.0	$	3,203.8

Realized gains and losses, net of tax, were not material for any of the periods presented.

As of December 31, 2017, and 2016, net unrealized losses on investments of $11.3 million and $8.6 million, net of tax, respectively, were included in accumulated other comprehensive loss in the accompanying Consolidated Balance Sheets.

The following tables present the breakdown of the available-for-sale investments with unrealized losses at December 31, 2017, and 2016 (in millions):



	Unrealized losses less than 12 months					Unrealized losses 12 months or greater					Total
December 31, 2017	Fair Value		Unrealized Losses			Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
Corporate securities	$	567.6	$	(2.1	)	$	277.0	$	(2.3	)	$	844.6	$	(4.4	)
U.S. treasuries	763.5		(2.5		)	206.2		(2.2		)	969.7		(4.7		)
U.S. government agencies	428.9		(1.3		)	345.5		(3.1		)	774.4		(4.4		)
Municipal securities	236.3		(1.3		)	51.7		(0.6		)	288.0		(1.9		)
	$	1,996.3	$	(7.2	)	$	880.4	$	(8.2	)	$	2,876.7	$	(15.4	)
December 31, 2016
Corporate securities	$	1,056.1	$	(5.0	)	$	—	$	—		$	1,056.1	$	(5.0	)
U.S. treasuries	357.1		(2.0		)	—		—			357.1		(2.0		)
U.S. government agencies	538.2		(2.9		)	—		—			538.2		(2.9		)
Municipal securities	728.8		(3.5		)	—		—			728.8		(3.5		)
	$	2,680.2	$	(13.4	)	$	—	$	—		$	2,680.2	$	(13.4	)

The unrealized losses on the available-for-sale investments are related to corporate securities and government securities. The Company determined these unrealized losses to be temporary. Factors considered in determining whether a loss is temporary included the length of time and extent to which the investment’s fair value has been less than the cost basis; the financial condition and near-term prospects of the investee; extent of the loss related to credit of the issuer; the expected cash flows from the security; the Company’s intent to sell the security; and whether or not the Company will be required to sell the security before the recovery of its amortized cost.

Foreign currency derivatives

The objective of the Company’s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency denominated sales, expenses, and intercompany balances and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (“USD”). The derivative assets and liabilities are measured using Level 2 fair value inputs.

Cash Flow Hedges. The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the European Euro (“EUR”), the British Pound (“GBP”), the Japanese Yen (“JPY”), and the Korean Won (“KRW”). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and Swiss Franc (“CHF”).

For these derivatives, the Company reports the after-tax gain or loss from the hedge as a component of accumulated other comprehensive loss in stockholders' equity and reclassifies into earnings in the same period in which the hedge transaction affects earnings. The Company reclassified a net loss of $2.9 million and net gains of $0.9 million and $7.2 million to revenue related to the hedged revenue transactions for the years ended December 31, 2017, 2016, and 2015, respectively. The amounts reclassified to expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented.

Other Derivatives Not Designated as Hedging Instruments. Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, and CHF.

These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):



	Years Ended December 31,
	2017			2016			2015
Recognized gains (losses) in interest and other income, net	$	(9.2	)	$	6.4		$	7.0
Foreign exchange gains (losses) related to balance sheet re-measurement	$	9.7		$	(5.6	)	$	(7.9	)

The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in USD) for derivatives and aggregate gross fair value outstanding at the end of each period were as follows (in millions):



	Derivatives Designated as Hedging Instruments				Derivatives Not Designated as Hedging Instruments
	December 31, 2017		December 31, 2016		December 31, 2017		December 31, 2016
Notional amounts:
Forward contracts	$	128.5	$	109.7	$	168.4	$	143.7
Gross fair value recorded in:
Prepaid and other current assets	$	0.9	$	6.2	$	1.2	$	5.6
Other accrued liabilities	$	2.9	$	1.0	$	4.6	$	0.6

Balance Sheet Details and Other Financial Information

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Details and Other Financial Information

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION

The following table provides details of the inventories (in millions):



	December 31,
	2017		2016
Inventory:
Raw materials	$	80.9	$	54.8
Work-in-process	19.7		13.4
Finished goods	140.6		114.1
Total inventory	$	241.2	$	182.3

The following table provides details of the property, plant, and equipment, net (in millions):



	December 31,
	2017			2016
Property, plant, and equipment, net:
Land	$	174.8		$	131.7
Building and building/leasehold improvements	230.5			199.5
Machinery and equipment	224.8			217.7
Operating lease assets	66.1			34.7
Computer and office equipment	44.8			41.3
Capitalized software	135.6			114.2
Construction-in-process	83.5			41.2
Gross property, plant, and equipment	960.1			780.3
Less: Accumulated depreciation*	(347.0		)	(321.9		)
Total property, plant, and equipment, net	$	613.1		$	458.4

*Accumulated depreciation associated with operating lease assets	$	(13.8	)	$	(6.8	)

The following table provides details of the other accrued liabilities—short term (in millions):



	December 31,
	2017		2016
Other accrued liabilities—short-term:
Taxes payable	$	63.1	$	40.4
Tolled product liability claims accrued	12.8		20.5
Other accrued liabilities	93.6		90.1
Total other accrued liabilities—short-term	$	169.5	$	151.0

The following table provides details of the other long-term liabilities (in millions):



	December 31,
	2017		2016
Other long-term liabilities:
Income taxes—long-term	$	286.8	$	84.9
Other long-term liabilities	40.3		27.7
Total other long-term liabilities	$	327.1	$	112.6

Supplemental Cash flow Information

The following table provides supplemental cash flow information (in millions):



	Years Ended December 31,
	2017		2016		2015
Income taxes paid	$	147.5	$	138.4	$	110.3
Supplemental non-cash investing activities:
Equipment transfers from inventory to property, plant, and equipment	$	65.8	$	39.3	$	26.7

Leases

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Leases

LEASES

Lease Receivables. Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):



	December 31,
	2017			2016
Gross lease receivables	$	128.0		$	104.3
Unearned income	(5.0		)	(4.8		)
Allowance for credit loss	(0.9		)	(0.6		)
Net investment in sales-type leases	122.1			98.9
Reported as:
Prepaids and other current assets	41.9			29.8
Intangible and other assets, net	80.2			69.1
Total, net	$	122.1		$	98.9

Contractual maturities of gross lease receivables as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	44.4
2019	37.0
2020	26.6
2021	13.1
2022	6.4
2023 and thereafter	0.5
Total	$	128.0

Operating Leases. The Company's operating lease terms are generally less than five years. Future minimum lease payments related to non-cancellable portion of operating leases as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	42.6
2019	41.2
2020	34.0
2021	19.5
2022	8.4
2023 and thereafter	0.7
Total	$	146.4

Contingent rental revenue relating to operating lease arrangements were not material for the periods presented.

Intangible Assets

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

INTANGIBLE ASSETS

The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December 31, 2017, and 2016 (in millions):



	December 31, 2017							December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Patents and developed technology	$	156.0	$	(140.2	)	$	15.8	$	158.7	$	(141.6	)	$	17.1
Distribution rights and others	9.2		(9.2		)	—		9.2		(9.1		)	0.1
Customer relationships	28.6		(18.4		)	10.2		28.6		(14.3		)	14.3
Total intangible assets	$	193.8	$	(167.8	)	$	26.0	$	196.5	$	(165.0	)	$	31.5

Amortization expense related to intangible assets was $12.9 million, $18.2 million, and $24.4 million for the years ended December 31, 2017, 2016, and 2015, respectively.

The estimated future amortization expense related to intangible assets as of December 31, 2017, is as follows (in millions):



Fiscal Year	Amount
2018	$	9.6
2019	4.6
2020	4.6
2021	3.4
2022	2.1
2023 and thereafter	1.7
Total	$	26.0

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Commitments And Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies

COMMITMENTS AND CONTINGENCIES

OPERATING LEASES

The Company leases space for operations in United States, Mexico, Japan, South Korea, and certain other foreign countries. The Company also leases automobiles for certain sales and field service employees. These leases have varying terms up to fifteen years.

Future minimum lease commitments under the Company’s operating leases as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	8.2
2019	5.8
2020	4.4
2021	3.4
2022	3.0
2023 and thereafter	16.8
Total	$	41.6

Other commitments include an estimated amount of approximately $478.1 million relating to the Company's open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with suppliers, for which we have not received the goods or services.

CONTINGENCIES

The Company is involved in a variety of claims, lawsuits, investigations and proceedings relating to securities laws, product liability, intellectual property, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. It is not possible to predict what the outcome of these matters will be and the Company cannot guarantee that any resolution will be reached on commercially reasonable terms, if at all.

A liability and related charge to earnings are recorded in the Company’s Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. Nevertheless, it is possible that additional future legal costs (including settlements, judgments, legal fees, and other related defense costs) could have a material adverse effect on the Company’s business, financial position, or future results of operations.

Purported Shareholder Class Action Lawsuits filed April 26, 2013 and May 24, 2013

On April 26, 2013, a purported class action lawsuit entitled Abrams v. Intuitive Surgical, et al., No. 5-13-cv-1920, was filed against a number of the Company’s current and former officers and directors in the United States District Court for the Northern District of California. A substantially identical complaint, entitled Adel v. Intuitive Surgical, et al., No. 5:13-cv-02365, was filed in the same court against the same defendants on May 24, 2013. The Adel case was voluntarily dismissed without prejudice on August 20, 2013.

On October 15, 2013, plaintiffs in the Abrams matter filed an amended complaint. The case has since been retitled In re Intuitive Surgical Securities Litigation, No. 5:13-cv-1920. The plaintiffs seek unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired the Company’s common stock between February 6, 2012, and July 18, 2013. The amended complaint alleges that the defendants violated federal securities laws by allegedly making false and misleading statements and omitting certain material facts in certain public statements and in the Company’s filings with the SEC. On November 18, 2013, the court appointed the Employees’ Retirement System of the State of Hawaii as lead plaintiff and appointed lead counsel. The Company filed a motion to dismiss the amended complaint on December 16, 2013, which was granted in part and denied in part on August 21, 2014. The plaintiffs elected not to further amend their complaint at that time. On October 22, 2014, the court granted the Company’s motion for leave to file a motion for reconsideration of the court’s August 21, 2014, order. The Company filed its motion for reconsideration on November 5, 2014. Following opposition and reply briefing, the court denied the motion on December 15, 2014, allowing the case to move forward on the claims that remained. The plaintiffs moved for class certification on September 1, 2015, and following opposition and reply briefing, the court held a hearing on the motion on January 21, 2016. While that motion remained pending, on October 11, 2016, the Company sent plaintiffs’ lead counsel, Labaton Sucharow LLP, a letter enclosing a draft motion for sanctions pursuant to Federal Rule of Civil Procedure 11, primarily based on statements to the court that lacked a proper factual basis. In response, on November 1, 2016, plaintiffs’ local counsel withdrew from the case entirely and withdrew their signatures from the disputed pleadings. On November 2, 2016, Labaton Sucharow LLP filed a motion for leave to file an amended complaint that did not include the disputed statements. On November 16, 2016, the Company filed an opposition to plaintiffs’ motion, along with an independent motion to strike the amended complaint and the pleadings from which plaintiffs’ local counsel withdrew their signatures. Following additional briefing, the motion for leave to amend and motion to strike were fully submitted to the court on November 23, 2016, and December 7, 2016, respectively. On December 22, 2016, the court entered an order granting plaintiffs’ motion for class certification. On January 5, 2017, the Company filed a Petition for Permission to Appeal from the order granting class certification in the U.S. Court of Appeals for the Ninth Circuit. On October 30, 2017, the court of appeals denied the Company’s petition. On January 12, 2017, plaintiffs sought leave to file a motion for partial reconsideration of the court’s class certification order, which the court granted on March 17, 2017. Plaintiffs filed the motion for reconsideration itself on April 3, 2017, and the Company filed its opposition on April 17, 2017. The court denied the motion on September 29, 2017. On January 25, 2017, the court entered an order granting plaintiffs’ motion for leave to amend the complaint and denying the Company’s motion to strike. On February 9, 2017, the Company moved to dismiss the amended complaint. Following opposition and reply briefing, the matter was fully submitted to the court on March 2, 2017. The court denied the motion on September 29, 2017. On July 13, 2017, the parties filed a stipulation vacating the case schedule, which the court entered on July 14, 2017. On November 8, 2017, the court entered a new case schedule, with trial set to begin on October 30, 2018. While the Company intends to vigorously defend itself, the actual outcome of this matter is dependent on many variables that are difficult to predict. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.

Purported Derivative Actions filed on February 3, 2014, February 21, 2014, March 21, 2014, June 3, 2014, and March 5, 2015

On February 3, 2014, an alleged stockholder, Robert Berg, caused a purported stockholder’s derivative lawsuit entitled Berg v. Guthart et al., No. 4:14-CV-00515, to be filed in the United States District Court for the Northern District of California. The lawsuit named the Company as a nominal defendant and named a number of the Company’s current and former officers and directors as defendants. The plaintiff sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and/or omissions made in connection with the Company’s financial reporting for the period between 2012 and early 2014. The plaintiff also sought a series of changes to the Company’s corporate governance policies and an award of attorneys’ fees. On April 3, 2014, the case was related to In re Intuitive Surgical Securities Litigation. On July 30, 2014, the court granted Berg’s motion to be appointed lead plaintiff, denied the City of Birmingham’s motion seeking such appointment (see below for additional description), and retitled the matter In re Intuitive Surgical, Inc. Shareholder Derivative Litigation, No. 4:14-CV-00515. On August 13, 2014, the plaintiffs filed a consolidated complaint, making allegations substantially similar to the allegations in the original complaint. On September 12, 2014, the Company filed a motion to dismiss the consolidated complaint, which the court denied on November 16, 2015. On January 26, 2016, the Company moved to stay this lawsuit in favor of Public School Teachers’ Pension and Retirement Fund of Chicago v. Guthart et al. (see below for additional description). While the motion was pending, the Company and the plaintiff agreed in principle that the plaintiff would file a motion to intervene in the Public School Teachers’ Pension and Retirement Fund of Chicago action. Following additional negotiations, the plaintiff filed an unopposed motion to intervene on April 29, 2016. After additional briefing, on May 23, 2016, the court in the Public School Teachers’ Pension and Retirement Fund of Chicago action granted the motion. Accordingly, on May 31, 2016, the parties filed a stipulation requesting that the court stay In re Intuitive Surgical, Inc. Shareholder Derivative Litigation, which the court granted on June 2, 2016. Additional discussions between the parties ensued, and on September 15, 2016, they executed a confidential Memorandum of Understanding that contained the essential terms of a settlement to which the parties agreed in principle. That settlement, as later finalized, provided for a dismissal with prejudice and release of all claims brought in both the In re Intuitive Surgical, Inc. Shareholder Derivative Litigation action and the Public School Teachers’ Pension and Retirement Fund of Chicago action, as well as City of Plantation Police Officers’ Employees’ Retirement System v. Guthart et al. (see below for additional description). The settlement, which also included terms that required the Company to reimburse the plaintiffs’ lawyers’ legal fees, was approved by the court in the Public School Teachers’ Pension and Retirement Fund of Chicago action on October 20, 2017, following the notice process described below. Accordingly, on December 26, 2017, the parties in the In re Intuitive Surgical, Inc. Shareholder Derivative Litigation action filed a stipulation requesting that the court dismiss the action with prejudice. The court entered the stipulation later the same day, and the matter is now resolved.

On February 21, 2014, a second alleged stockholder caused a substantially similar purported stockholder’s derivative lawsuit entitled Public School Teachers’ Pension and Retirement Fund of Chicago v. Guthart et al., No. CIV 526930, to be filed in the Superior Court of the State of California, County of San Mateo, against the same parties and seeking the same relief. On March 26, 2014, the case was removed to the United States District Court for the Northern District of California, where it was related to In re Intuitive Surgical Securities Litigation and Berg v. Guthart on April 30, 2014. The district court remanded the case back to San Mateo County Superior Court on June 30, 2014. On August 28, 2014, the Company filed a motion seeking to stay the case in favor of the federal action and asking that the plaintiff be required to post a bond on the grounds that the action was duplicative and was not in the Company’s best interests. On November 13, 2014, the superior court entered an order denying in part the Company’s motion to stay and denying the Company’s request for plaintiff’s bond. On November 18, 2014, the Company petitioned the First Appellate District of the California, Court of Appeal for a writ of mandate directing the superior court to stay the case in its entirety. At the same time, the Company requested an immediate stay of proceedings pending resolution of the petition. On November 19, 2014, the court of appeal granted the Company’s request for an immediate stay of the proceedings and set a briefing schedule for the petition. The plaintiff filed its opposition to the petition on December 8, 2014, and the Company filed its reply on December 22, 2014. The petition was denied on January 8, 2015. On January 20, 2015, the Company filed a demurrer (moved to dismiss the complaint). The plaintiff filed its opposition to the demurrer on February 10, 2015, and the Company filed its reply on February 20, 2015. A hearing was held on February 27, 2015, and the court overruled the demurrer on March 27, 2015. The court’s order was entered on April 2, 2015. On June 19, 2015, the Company moved for summary judgment, and a hearing on the Company’s motion was set for September 4, 2015. On July 6, 2015, the court amended the case schedule, and the Company withdrew its motion for summary judgment. The court later further amended the case schedule, and trial was eventually reset for September 16, 2016. On May 23, 2016, the court granted an unopposed motion to intervene filed by the plaintiffs in In re Intuitive Surgical, Inc. Shareholder Derivative Litigation and City of Birmingham Relief and Retirement System v. Guthart et al. (see above and below for additional description). The Company filed a new motion for summary judgment on June 1, 2016, and the plaintiff filed a motion for summary adjudication regarding certain affirmative defenses on June 2, 2016. Following opposition and reply briefing, the court heard argument on the motions for summary judgment and summary adjudication on August 24, 2016. While the motions were pending, on September 15, 2016, the parties executed the confidential Memorandum of Understanding described above, which contained the essential terms of a settlement to which the parties agreed in principle. The parties notified the court of the Memorandum of Understanding on September 15, 2016, and on September 16, 2016, the court entered an order vacating the trial date and ruling that the motions for summary judgment and summary adjudication (along with other pre-trial motions) were moot. The parties finalized the settlement over the ensuing months, appearing before the court periodically to keep it apprised of their progress. The final settlement provided for a dismissal with prejudice and release of all claims brought in the Public School Teachers’ Pension and Retirement Fund of Chicago action, as well as the In re Intuitive Surgical, Inc. Shareholder Derivative Litigation action and the City of Plantation Police Officers’ Employees’ Retirement System action and the other similar derivative cases (see above and below, respectively, for additional description). The settlement also included terms that required the Company to reimburse the plaintiffs’ lawyers’ legal fees. On July 7, 2017, the plaintiff filed a motion for preliminary approval of the settlement, and on July 18, 2017, the Company filed a statement of non-opposition. On August 9, 2017, the court entered an order preliminarily approving settlement, providing for notice to the Company’s shareholders, and setting a final settlement hearing. On October 20, 2017, the final settlement was approved by the court. During the year ended December 31, 2017, the Company recorded $11.7 million, respectively, of pre-tax charges to reflect the cost of settling this matter. As of December 31, 2017, the final settlement was paid in full.

On March 21, 2014, a third alleged stockholder caused a substantially similar purported stockholder’s derivative lawsuit entitled City of Birmingham Relief and Retirement System v. Guthart et al., No. 5-14-CV-01307, to be filed in the United States District Court for the Northern District of California against the same parties and seeking the same relief. On April 8, 2014, the lawsuit was related to In re Intuitive Surgical Securities Litigation and Berg v. Guthart. On July 30, 2014, the court consolidated the case with Berg v. Guthart and, as noted above, granted Berg’s motion to be appointed lead plaintiff and denied the City of Birmingham’s motion seeking such appointment. Accordingly, the City of Birmingham Relief and Retirement System action was resolved by the settlement of the In re Intuitive Surgical, Inc. Shareholder Derivative Litigation action (see above for additional description), and was subject to the December 26, 2017 stipulated dismissal of that action with prejudice. The matter is now resolved.

On June 3, 2014, a fourth alleged stockholder caused a substantially similar purported stockholder’s derivative lawsuit entitled City of Plantation Police Officers’ Employees’ Retirement System v. Guthart et al., C.A. No. 9726-CB, to be filed in the Court of Chancery of the State of Delaware. The Company filed a motion to stay proceedings in favor of the earlier-filed stockholder derivative lawsuits pending in federal and state courts in California. In light of the Company’s motion, the plaintiff agreed to a stay of all proceedings in the case in favor of the earlier-filed actions. While the case was stayed, the parties agreed that the plaintiff would file a motion to intervene in the Public School Teachers’ Pension and Retirement Fund of Chicago action (see above for additional description). The plaintiff filed an unopposed motion to intervene on April 29, 2016. After additional briefing, on May 23, 2016, the court in the Public School Teachers’ Pension and Retirement Fund of Chicago action granted the plaintiff’s motion. However, on June 21, 2016, in response to discovery requests, the plaintiff admitted that it did not continuously hold the Company’s stock during all relevant times. Accordingly, on July 21, 2016, the plaintiff filed a request for dismissal as an additional plaintiff in the Public School Teachers’ Pension and Retirement Fund of Chicago action, which the court in that action granted with prejudice on July 22, 2016. On September 15, 2016, the parties executed the confidential Memorandum of Understanding described above, which contained the essential terms of a settlement to which the parties had agreed in principle. That settlement, as later finalized, provided for a dismissal with prejudice and release of all claims brought in the City of Plantation Police Officers’ Employees’ Retirement System action, as well as both the In re Intuitive Surgical, Inc. Shareholder Derivative Litigation action and the Public School Teachers’ Pension and Retirement Fund of Chicago action (see above for additional description). The settlement, which also included terms that required the Company to reimburse the plaintiffs’ lawyers’ legal fees, was approved by the court in the Public School Teachers’ Pension and Retirement Fund of Chicago action as described above. Accordingly, on December 26, 2017, the parties in the City of Plantation Police Officers’ Employees’ Retirement System action filed a stipulation requesting that the court dismiss the action with prejudice. The court entered the stipulation on December 29, 2017, and the matter is now resolved.

On March 5, 2015, a fifth alleged stockholder caused a substantially similar purported stockholder’s derivative lawsuit entitled Back v. Guthart et al., No. 3:15-CV-01037, to be filed in the United States District Court for the Northern District of California. On April 7, 2015, the lawsuit was related to In re Intuitive Surgical Securities Litigation and Berg v. Guthart. The Company filed a motion to dismiss the complaint on July 10, 2015. On August 13, 2015, the parties stipulated to a complete stay of the matter and the court entered an order reflecting the stay on August 17, 2015. On September 11, 2017, the plaintiff filed a motion to lift the stay and reopen the case and for leave to file amended complaint. On September 25, 2017, the individual defendants filed an opposition to plaintiffs’ motion, which the Company joined on September 26, 2017. Plaintiff filed his reply October 2, 2017, and the Court set a hearing for January 25, 2018. While the motion was pending however, the settlement described above was approved by the court in the Public School Teachers’ Pension and Retirement Fund of Chicago action. Accordingly, on November 22, 2017, the parties in the Back action filed a stipulation requesting that the court dismiss the action with prejudice. The court entered the stipulation later the same day, and the matter is now resolved.

Product Liability Litigation

The Company is currently named as a defendant in approximately 43 individual product liability lawsuits filed in various state and federal courts by plaintiffs who allege that they or a family member underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases death as a result of such surgery. The Company has also received a large number of product liability claims from plaintiffs’ attorneys, many of which are subject to certain tolling agreements further discussed below. The Company has also been named as a defendant in a multi-plaintiff lawsuit filed in Missouri state court. In total, plaintiffs in that case seek damages on behalf of 55 patients from 22 different states who had surgeries in which their surgeons used the da Vinci Surgical System. Several of the filed cases have trial dates in the next 12 months.

The cases raise a variety of allegations including, to varying degrees, that plaintiffs’ injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company’s part to provide adequate training resources to the healthcare professionals who performed plaintiffs’ surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages.

Plaintiffs’ attorneys have also engaged in well-funded national advertising efforts seeking patients dissatisfied with surgery utilizing the da Vinci Surgical System. The Company has received a significant number of such claims from plaintiffs’ attorneys that it believes are a result of these advertising efforts. A substantial number of claims relate to alleged complications from surgeries performed with certain versions of Monopolar Curved Scissor (“MCS”) instruments which included an MCS tip cover accessory that was the subject of a market withdrawal in 2012 and MCS instruments that were the subject of a recall in 2013. In an effort to avoid the expense and distraction of defending multiple lawsuits, the Company entered into tolling agreements to pause the applicable statutes of limitations for many of these claims and engaged in confidential mediation efforts.

After an extended confidential mediation process with legal counsel for many of the claimants covered by the tolling agreements, the Company determined during 2014 that, while it denies any and all liability, in light of the costs and risks of litigation, settlement of certain claims was appropriate. During the years ended December 31, 2017, 2016, and 2015, the Company recorded $16.3 million, $8.3 million, and $13.8 million, respectively, of pre-tax charges to reflect the estimated cost of settling a number of the product liability claims covered by the tolling agreements. As of December 31, 2017, and 2016, a total of $12.8 million and $20.5 million, respectively, were included in other accrued liabilities in the accompanying Consolidated Balance Sheets related to the pending product-liability cases and the tolled product liability claims.

The Company’s estimate of the anticipated cost of resolving both the pending cases and the tolled claims is based on negotiations with attorneys for claimants who have participated in the mediation process. Nonetheless, it is possible that more claims will be made by additional individuals and that the claimants whose claims were not resolved through the mediation program, as well as those claimants who have not participated in mediations, will choose to pursue greater amounts in a court of law. Consequently, the final outcome of these claims is dependent on many variables that are difficult to predict and the ultimate cost associated with these product liability claims may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on the Company’s business, financial position, and future results of operations. Although there is a reasonable possibility that a loss in excess of the amount recognized exists, the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.

In February 2011, the Company was named as a defendant in a product liability action that had originally been filed in Washington State Superior Court for Kitsap County against the healthcare providers and hospital involved in a decedent’s surgery on such decedent’s behalf (Josette Taylor, as Personal Representative of the Estate of Fred E. Taylor, deceased; and on behalf of the Estate of Fred E. Taylor v. Intuitive Surgical, Inc., No. 09-2-03136-5). In Taylor, plaintiff asserted wrongful death and product liability claims against the Company, generally alleging that the decedent died four years after surgery as a result of injuries purportedly suffered during the surgery, which was conducted with the use of the da Vinci Surgical System. The plaintiff in Taylor asserted that such injuries were caused, in whole or in part, by the Company’s purported failure to properly train, warn, and instruct the surgeon. The lawsuit sought unspecified damages for past medical expenses, pain and suffering, loss of consortium as well as punitive damages. A trial commenced on April 15, 2013. On May 23, 2013, the jury returned a defense verdict, finding that the Company was not negligent. Judgment was entered in the Company’s favor on June 7, 2013. Subsequent to the verdict, the plaintiff filed a notice of appeal. That appeal was denied on July 7, 2015. On July 27, 2015, plaintiff filed a motion for reconsideration with the court of appeal; the court of appeal denied the motion for reconsideration on August 10, 2015. On September 9, 2015, plaintiff filed a Petition for Review with the Washington State Supreme Court (“Washington Supreme Court”). On February 10, 2016, the Washington Supreme Court issued an order granting the plaintiff’s Petition for Review. Oral argument on the appeal before the Washington Supreme Court was heard on June 7, 2016. On February 9, 2017, the Washington Supreme Court vacated the defense verdict and remanded the case for retrial. In November 2017, the Company reached a confidential settlement with the plaintiff, which did not have a material adverse effect on the Company’s business, financial position, or future results of operations.

Patent Litigation

On June 30, 2017, Ethicon LLC, Ethicon Endo-Surgery, Inc., and Ethicon US LLC (collectively, “Ethicon”) filed a complaint for patent infringement against the Company in the United States District Court for the District of Delaware. The complaint, which was served on the Company on July 12, 2017, alleges that the Company’s EndoWrist Stapler instruments infringe several of Ethicon’s patents. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.

Stockholders' Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Stockholders' Equity

STOCKHOLDERS’ EQUITY

STOCK REPURCHASE PROGRAM

The Company’s Board of Directors (the “Board”) has authorized an aggregate of $6.2 billion of funding for the Company’s common stock repurchase program (the “Repurchase Program”) since originally established in March 2009, of which the most recent authorization occurred in December 2016 when the Board increased the authorized amount available under the Repurchase Program to $3.0 billion. As of December 31, 2017, the remaining amount of share repurchases authorized by the Board under the Repurchase Program was approximately $717.5 million.

On January 24, 2017, the Company entered into an accelerated share repurchase program (the “ASR Program”) with Goldman Sachs & Co. LLC (“Goldman”) to repurchase $2.0 billion of the Company’s common stock. On January 27, 2017, the Company made a payment of $2.0 billion to Goldman and Goldman delivered to the Company an initial delivery of approximately 7.3 million shares of the Company’s common stock, which represents 80% of the payment amount divided by the closing price of the Company’s common stock on January 23, 2017. Settlement was based on the daily volume-weighted average price per share of the Company’s common stock during the repurchase period, less a discount, and resulted in the Company being required either to deliver shares of common stock or to make a cash payment to Goldman. On December 7, 2017, the Company completed the ASR Program by making a final settlement payment of $274.0 million to Goldman.

The following table provides the stock repurchase activities during the years ended December 31, 2017, 2016, and 2015 (in millions, except per share amounts):



	Years Ended December 31,
	2017		2016		2015
Shares repurchased	7.3		0.2		1.1
Average price per share	$	310.32	$	201.70	$	167.41
Value of shares repurchased	$	2,274.0	$	42.5	$	183.7

The Company uses the par value method of accounting for its stock repurchases. As a result of the share repurchases during the years ended December 31, 2017, 2016, and 2015, the Company reduced common stock and additional paid-in capital by an aggregate of $152.0 million, $4.1 million, and $16.3 million, respectively, and charged $2,122.0 million, $38.4 million, $167.4 million, respectively, to retained earnings.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The components of accumulated other comprehensive income (loss) net of tax, for the years ended December 31, 2017, and 2016, are as follows (in millions):



	Year Ended December 31, 2017
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for-Sale Securities			Foreign Currency Translation Gains (Losses)			Employee Benefit Plans			Total
Beginning balance	$	5.0		$	(8.6	)	$	(1.3	)	$	(4.0	)	$	(8.9	)
Other comprehensive income (loss) before reclassifications	(8.6		)	(2.7		)	3.6			(0.3		)	(8.0		)
Reclassified from accumulated other comprehensive loss	1.2			—			—			0.2			1.4
Net current-period other comprehensive income (loss)	(7.4		)	(2.7		)	3.6			(0.1		)	(6.6		)
Ending balance	$	(2.4	)	$	(11.3	)	$	2.3		$	(4.1	)	$	(15.5	)

	Year Ended December 31, 2016
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for-Sale Securities			Foreign Currency Translation Gains (Losses)			Employee Benefit Plans			Total
Beginning balance	$	1.5		$	(4.2	)	$	(3.3	)	$	(3.5	)	$	(9.5	)
Other comprehensive income (loss) before reclassifications	4.1			(4.6		)	2.0			(0.7		)	0.8
Reclassified from accumulated other comprehensive loss	(0.6		)	0.2			—			0.2			(0.2		)
Net current-period other comprehensive income (loss)	3.5			(4.4		)	2.0			(0.5		)	0.6
Ending balance	$	5.0		$	(8.6	)	$	(1.3	)	$	(4.0	)	$	(8.9	)

Share-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

SHARE-BASED COMPENSATION

Stock Plans

2010 Incentive Award Plan. In April 2010, the Company’s stockholders approved the 2010 Incentive Award Plan (“2010 Plan”). Under this plan, the Company issues nonqualified stock options (“NSOs”) and restricted stock units (“RSUs”) to employees and certain consultants. The 2010 Plan generally permits NSOs to be granted at no less than the fair market value of the common stock on the date of grant, with terms of 10 years from the date of grant. The 2010 Plan expires in 2020. In April 2017, the Company’s stockholders approved an amended and restated 2010 Plan to provide for an increase in the number of shares of common stock reserved for issuance from 21,150,000 to 24,450,000. As of December 31, 2017, approximately 6.2 million shares were reserved for future issuance under the 2010 Plan. A maximum of 2.7 million of these shares can be awarded as RSUs.

2009 Employment Commencement Incentive Plan. In October 2009, the Board adopted the 2009 Employment Commencement Incentive Plan (“New Hire Plan”). The New Hire Plan provides for the shares to be used exclusively for the grant of RSUs and NSOs to new employees (“New Hire Options”), who were not previously employees or non-employee directors of the Company. The Compensation Committee approves all equity awards under the New Hire Plan, which are granted to newly-hired employees once a month on the fifth business day of each month after their hire. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years.

In April 2015, the Board of Directors amended and restated the New Hire Plan to provide for an increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the New Hire Plan from 3,465,000 to 4,365,000. As of December 31, 2017, approximately 43,000 shares were reserved for future issuance under the New Hire Plan. However, the Company intends to no longer issue grants from the New Hire Plan in the future and plans to instead utilize the 2010 Plan to make grants to new employees.

2000 Equity Incentive Plan. In March 2000, the Board adopted the 2000 Equity Incentive Plan (“2000 Plan”), which took effect upon the closing of the Company’s initial public offering. Under this plan, certain employees, consultants, and non-employee directors could be granted Incentive Stock Options (“ISOs”) and Nonstatutory Stock Options (“NSOs”) to purchase shares of the Company’s common stock. The 2000 Plan permitted ISOs to be granted at an exercise price not less than the fair value on the date of the grant and NSOs at an exercise price not less than 85% of the fair value on the date of grant. Options granted under the 2000 Plan generally expire 10 years from the date of grant and become exercisable upon grant subject to repurchase rights in favor of the Company until vested. The 2000 Plan expired in March 2010. However, options granted prior to the plan’s expiration continue to remain outstanding until their original expiration date.

Employee Option Vesting. The Company makes annual option grants on February 15 (or the next business day if the date is not a business day) and on August 15 (or the next business day if the date is not a business day). The February 15 grants vest 6/48 upon completion of 6 months service and 1/48 per month thereafter. The August 15 stock option grants vest 7/48 at the end of one month and 1/48 per month thereafter through a 3.5-year vesting period.

New Hire Options generally vest 12/48 upon completion of one year service and 1/48 per month thereafter. Option vesting terms are determined by the Board and, in the future, may vary from past practices.

2000 Non-Employee Directors’ Stock Option Plan. In March 2000, the Board of Directors adopted the 2000 Non-Employee Directors’ Stock Option Plan (the “Directors’ Plan”). In October 2009, the automatic evergreen increase provisions were eliminated so that no further automatic increases will be made to the number of shares reserved for issuance under the Directors’ Plan. In addition, the common stock authorized for issuance under the Directors’ Plan was reduced to 450,000. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years. Prior to 2016, initial stock option grants to new non-employee directors vest over a three-year period with 12/36 of the shares vesting after one year from the date of grant and 1/36 of the shares vesting monthly thereafter. Annual stock option grants vest one year from the date of the grant. Since 2016, new non-employee directors receive pro-rated stock option grants that vest on the same term as the annual stock option grants. As of December 31, 2017, approximately 0.1 million shares were reserved for future issuance under the Directors’ Plan.

2000 Employee Stock Purchase Plan. In March 2000, the Board adopted the 2000 Employee Stock Purchase Plan (the “ESPP”). Employees are generally eligible to participate in the ESPP if they are customarily employed by the Company for more than 20 hours per week and more than 5 months in a calendar year and are not 5% stockholders of the Company. Under the ESPP, eligible employees may select a rate of payroll deduction up to 15% of their eligible compensation subject to certain maximum purchase limitations. The duration for each offering period is 24 months and is divided into four purchase periods of approximately six months in length. Offerings are concurrent. The purchase price of the shares under the offering is the lesser of 85% of the fair market value of the shares on the offering date or 85% of the fair market value of the shares on the purchase date. A two-year look-back feature in the ESPP causes the offering period to reset if the fair value of the Company’s common stock on the first or last day of the purchase period is less than that on the original offering date. ESPP purchases by employees are settled with newly-issued common stock from the ESPP’s previously authorized and available pool of shares. In April 2017, the Company’s stockholders approved an amended and restated ESPP to provide for an increase in the number of shares of common stock reserved for issuance from 6,090,315 to 7,590,315.

The Company issued 0.2 million, 0.2 million, and 0.3 million shares under the ESPP, representing approximately $38.3 million, $32.5 million, and $31.2 million in employee contributions for the years ended December 31, 2017, 2016, and 2015, respectively. As of December 31, 2017, there were approximately 1.6 million shares reserved for future issuance under the ESPP.

Restricted Stock Units. Equity awards granted to employees and non-employee directors include a mix of stock options and RSUs. The RSUs to employees vest in one-fourth increments annually over a four-year period. Prior to 2016, initial RSUs granted to new non-employee directors are vested in one-third increments over a three-year period. Annual RSU grants to non-employee directors vest one year from the date of grant. Since 2016, new non-employee directors receive pro-rated RSU grants that vest on the same term as the annual RSU grants. The number of shares issued on the date the RSUs vest is net of the minimum statutory tax withholdings, which are paid in cash to the appropriate taxing authorities on behalf of the Company’s employees.

Stock Option Information

Option activity during fiscal 2017 under all the stock plans was as follows (in millions, except per share amounts):



	Stock Options Outstanding
	Number Outstanding		Weighted Average Exercise Price Per Share
Balance at December 31, 2016	9.3		$	148.36
Options granted	0.7		$	287.11
Options exercised	(2.7	)	$	140.70
Options forfeited/expired	(0.1	)	$	204.94
Balance at December 31, 2017	7.2		$	164.16

The aggregate intrinsic value of stock options exercised under our stock plans determined as of the date of option exercise was $379.9 million, $273.3 million, and $196.5 million during the years ended December 31, 2017, 2016, and 2015, respectively. Cash received from option exercises and employee stock purchase plans for the years ended December 31, 2017, 2016, and 2015, was $415.5 million, $580.9 million, and $361.1 million, respectively. The income tax benefit from stock options exercised was $118.9 million for the year ended December 31, 2017.

The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2017 (number of shares and aggregate intrinsic value in millions):



	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)		Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)
$31.96 - $113.73	1.6	2.3	$	92.43			1.6		$	92.43
$114.61 - $153.05	1.5	5.9	$	140.19			1.4		$	139.87
$155.57 - $172.44	1.6	5.4	$	169.56			1.4		$	169.67
$172.76 - $213.77	1.4	6.7	$	184.30			1.0		$	185.29
$213.97 - $391.04	1.1	9.1	$	266.31			0.3		$	250.46
Total	7.2	5.6	$	164.16	$	1,447.2	5.7	4.9	$	147.32	$	1,234.4


(1)	The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $364.94 at December 31, 2017, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.

As of December 31, 2017, a total of 7.1 million shares of stock options vested and expected to vest had a weighted average remaining contractual life of 5.6 years, an aggregate intrinsic value of $1,429.6 million, and a weighted average exercise price of $162.50.

Restricted Stock Units Information

RSU activity for the year ended December 31, 2017, was as follows (in millions, except per share amounts):



	Shares		Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2016	1.8		$	174.72
Granted	1.0		$	249.34
Vested	(0.6	)	$	171.42
Forfeited	(0.1	)	$	204.08
Unvested balance at December 31, 2017	2.1		$	209.55

As of December 31, 2017, 1.9 million shares of RSUs were expected to vest with an aggregate intrinsic value of $700.1 million. The aggregate vesting date fair value of RSUs vested was $144.2 million, $65.3 million, and $29.5 million during the years ended December 31, 2017, 2016, and 2015, respectively.

Share-Based Compensation Expense

The following table summarizes share-based compensation expense (in millions):



	Years Ended December 31,
	2017		2016		2015
Cost of sales—products	$	28.1	$	25.2	$	22.8
Cost of sales—services	14.0		12.4		12.9
Total cost of sales	42.1		37.6		35.7
Selling, general and administrative	111.8		97.4		94.7
Research and development	56.0		43.0		37.7
Share-based compensation expense before income taxes	209.9		178.0		168.1
Income tax effect	49.2		56.1		51.8
Share-based compensation expense after income taxes	$	160.7	$	121.9	$	116.3

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s share-based compensation plans and rights to acquire stock granted under the Company’s employee stock purchase plan. The weighted average estimated fair values of stock options, the rights to acquire stock granted, and RSUs, as well as the weighted average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December 31, 2017, 2016, and 2015, were as follows:



	Years Ended December 31,
STOCK OPTION PLANS	2017			2016			2015
Risk-free interest rate	1.8		%	1.1		%	1.6		%
Expected term (years)	4.1			4.2			4.3
Volatility	25		%	26		%	28		%
Fair value at grant date	$	67.03		$	47.06		$	43.82
EMPLOYEE STOCK PURCHASE PLAN
Risk-free interest rate	1.2		%	0.6		%	0.4		%
Expected term (years)	1.2			1.2			1.2
Volatility	28		%	30		%	31		%
Fair value at grant date	$	79.77		$	57.57		$	48.91
RESTRICTED STOCK UNITS
Fair value at grant date	$	249.34		$	184.59		$	170.64

As share-based compensation expense recognized in the Consolidated Statements of Income during the years ended December 31, 2017, 2016, and 2015, is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. For share-based compensation accounting, the Company elected to continue estimating expected forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimated.

As of December 31, 2017, there were a total of $69.9 million, $278.9 million, and $18.4 million of total unrecognized compensation expense related to unvested stock options, restricted stock units, and employee stock purchases, respectively. The unrecognized compensation expense is expected to be recognized over a weighted average period of 2.3 years for unvested stock options, 2.4 years for unvested restricted stock units, and 1.5 years for rights granted to acquire common stock under the ESPP.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

Income before provision for income taxes for the years ended December 31, 2017, 2016, and 2015, consisted of the following (in millions):



	Years Ended December 31,
	2017		2016		2015
U.S.	$	765.0	$	653.0	$	425.1
Foreign	331.5		327.8		333.4
Total income before provision for income taxes	$	1,096.5	$	980.8	$	758.5

The provision for income taxes for the years ended December 31, 2017, 2016, and 2015, consisted of the following (in millions):



	Years Ended December 31,
	2017			2016		2015
Current
Federal	$	352.1		$	207.0	$	148.7
State	13.0			13.4		8.4
Foreign	8.7			5.4		7.6
	$	373.8		$	225.8	$	164.7
Deferred
Federal	$	65.5		$	18.3	$	7.5
State	(0.4		)	0.6		0.5
Foreign	(2.4		)	0.2		(3.0		)
	$	62.7		$	19.1	$	5.0
Total income tax expense	$	436.5		$	244.9	$	169.7

Income tax expense differs from amounts computed by applying the statutory federal income rate of 35% for the years ended December 31, 2017, 2016, and 2015, as a result of the following (in millions):



	Years Ended December 31,
	2017			2016			2015
Federal tax at statutory rate	$	383.8		$	343.3		$	265.5
Increase (reduction) in tax resulting from:
State taxes, net of federal benefits	16.0			14.0			8.9
Foreign rate differential	(107.3		)	(86.2		)	(67.4		)
Research and development credit	(15.3		)	(7.8		)	(6.4		)
Share-based compensation not benefited	10.8			3.6			6.9
Domestic production activities deduction	(7.9		)	(8.0		)	(5.3		)
Reversal of unrecognized tax benefits	(62.4		)	(15.8		)	(6.4		)
Reversal of share-based compensation from intercompany charges	—			—			(25.0		)
Tax Cuts and Jobs Act impact	317.8			—			—
Excess tax benefits	(102.8		)	—			—
Other	3.8			1.8			(1.1		)
Total income tax expense	$	436.5		$	244.9		$	169.7

Deferred income taxes reflect tax carry forwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows (in millions):



	December 31,
	2017			2016
Deferred tax assets:
Share-based compensation expense	$	79.1		$	122.2
Expenses deducted in later years for tax purposes	29.7			47.4
Research and other credits	27.5			15.6
Other	10.5			9.8
Gross deferred tax assets	$	146.8		$	195.0
Valuation allowance	(29.4		)	(17.2		)
Deferred tax assets	$	117.4		$	177.8
Deferred tax liabilities:
Fixed assets	$	(26.3	)	$	(25.2	)
Intangible assets	(3.6		)	(2.3		)
Other	(0.2		)	(0.2		)
Deferred tax liabilities	$	(30.1	)	$	(27.7	)
Net deferred tax assets	$	87.3		$	150.1

The 2017 Tax Act was enacted on December 22, 2017. The 2017 Tax Act includes a number of changes in existing tax law impacting businesses, including a one-time deemed repatriation of cumulative undistributed foreign earnings and a permanent reduction in the U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. Under U.S. GAAP, changes in tax rates and tax law are accounted for in the period of enactment and deferred tax assets and liabilities are measured at the enacted tax rate. Consistent with guidance issued by the Securities Exchange Commission (“SEC”), which provides for a measurement period of one year from the enactment date to finalize the accounting for effects of the 2017 Tax Act, the Company provisionally recorded an income tax expense of $317.8 million related to the 2017 Tax Act. Based on information available, the Company estimated the cumulative undistributed foreign earnings to be approximately $1,873.8 million and recorded a provisional estimate of $270.2 million of income tax expense related to the one-time deemed repatriation toll charge, which will be payable over eight years. As a result of the 2017 Tax Act, the Company can repatriate the cumulative undistributed foreign earnings back to the U.S. when needed with minimal U.S. income tax consequences other than the one-time deemed repatriation toll charge. The Company is still evaluating whether to change its indefinite reinvestment assertion in light of the 2017 Tax Act and consider that conclusion to be incomplete under guidance issued by the SEC. If the Company subsequently changes its assertion during the measurement period, the Company will account for the change in assertion as part of the 2017 Tax Act enactment.

In addition, the Company recorded a provisional estimate of $47.6 million income tax expense due to the re-measurement of its net deferred tax assets at a U.S. federal statutory rate that was reduced from 35% to 21%. For the GILTI provisions of the 2017 Tax Act, a provisional estimate could not be made as the Company has not yet completed its assessment or elected an accounting policy to either recognize deferred taxes for basis differences expected to reverse as GILTI or to record GILTI as period costs if and when incurred.

In accordance with SEC guidance, provisional amounts may be refined as a result of additional guidance from, and interpretations by, U.S. regulatory and standard-setting bodies, and changes in assumptions. In the subsequent period, provisional amounts will be adjusted for the effects, if any, of interpretative guidance issued after December 31, 2017, by the U.S. Department of the Treasury. The effects of the 2017 Tax Act may be subject to changes for items that were previously reported as provisional amounts, as well as any element of the 2017 Tax Act that a provisional estimate could not be made, and such changes could be material.

The Company adopted ASU No. 2016-09 in the first quarter of 2017, which resulted in excess tax benefits associated with employee equity plans of $102.8 million being recognized in the income tax provision for the year ended December 31, 2017. Excess tax benefits associated with employee equity plans was previously recorded in additional paid-in capital and the adoption of this ASU resulted in reducing the Company’s effective tax rate by 9.4 percentage points for the year ended December 31, 2017. The amount of excess tax benefits or deficiencies will fluctuate from period to period based on the price of the Company’s stock, the volume of share-based instruments settled or vested, and the value assigned to employee equity awards under U.S. GAAP.

The Company’s tax holiday obtained in 2007 for business operations in Switzerland ended on December 31, 2017. The tax benefit from the tax holiday for the year ended December 31, 2017, was approximately $10.9 million, or $0.09 per diluted share. The Company received a new tax ruling in Switzerland for new business operations. The new ruling is effective for years 2018 through 2022, which will be extended for the next five years thereafter, to the extent certain terms and conditions continue to be met. The new ruling would allow for a reduced cantonal tax rate based on various thresholds of investment, including the ownership, development, and use of the non-U.S. intellectual property rights and employment in such jurisdiction. The transfer of ownership of such intellectual property rights to the Company's Swiss entity did not impact the Consolidated Financial Statements for the periods presented.

As of December 31, 2017, and 2016, the Company had valuation allowances of $29.4 million and $17.2 million, respectively, primarily related to California deferred tax assets generated by California R&D credit forwards which have no expiration period. The Company recorded a valuation allowance against its California deferred tax assets as it is more likely than not these deferred tax assets will not be realized as a result of the computation of California taxes under the single sales factor.

The Company recorded a net decrease of its gross unrecognized tax benefits of approximately $40.6 million during the year ended December 31, 2017. The net decrease was primarily due to the reversal of gross unrecognized tax benefits in connection with the expiration of certain statutes of limitation in various jurisdictions and associated re-measurement of uncertain tax position, partially offset by increases related to 2017 uncertain tax positions. The Company had gross unrecognized tax benefits of approximately $65.4 million, $106.0 million, and $92.4 million as of December 31, 2017, 2016, and 2015, respectively, which if recognized, would result in a reduction of the Company’s effective tax rate. The Company included interest expense accrued on unrecognized tax benefits as a component of its income tax expense. As of December 31, 2017, 2016, and 2015, gross interest related to unrecognized tax benefits accrued was approximately $1.8 million, $3.7 million, and $2.9 million, respectively. A majority of the Company's net unrecognized tax benefits and related interest is presented in Other accrued liabilities on the Consolidated Balance Sheets.

A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December 31, 2017, 2016, and 2015, are as follows (in millions):



	Years Ended December 31,
	2017			2016			2015
Beginning balance	$	106.0		$	92.4		$	75.5
Increases related to tax positions taken during the current year	21.1			29.9			28.9
Increases related to tax positions taken during a prior year	—			—			0.3
Decreases related to tax positions taken during a prior year	(46.5		)	(0.5		)	—
Decreases related to settlements with tax authorities	(0.5		)	—			(11.4		)
Decreases related to expiration of statute of limitations	(14.7		)	(15.8		)	(0.9		)
Ending balance	$	65.4		$	106.0		$	92.4

The Company files federal, state and foreign income tax returns in many U.S. and OUS jurisdictions. Years before 2014 are closed for the significant jurisdictions. Certain of the Company’s unrecognized tax benefits could change due to activities of various tax authorities, including potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect the Company’s effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, the Company cannot estimate the range of reasonably possible change in unrecognized tax benefits that may occur in the next 12 months.

The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company's management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company’s provision for income taxes. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

Net Income Per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net Income Per Share

NET INCOME PER SHARE

The following table presents the computation of basic and diluted net income per share (in millions, except per share amounts):



	Years Ended December 31,
	2017		2016		2015
Numerator:
Net income	$	660.0	$	735.9	$	588.8
Denominator:
Weighted-average shares outstanding in basic calculation	111.7		114.9		111.3
Add: dilutive effect of potential common shares	4.6		3.0		2.4
Weighted-average shares used in computing diluted net income per share	116.3		117.9		113.7
Net income per share:
Basic	$	5.91	$	6.40	$	5.29
Diluted	$	5.67	$	6.24	$	5.18

Share-based compensation awards of approximately 0.2 million, 0.6 million, and 5.0 million shares for the years ended December 31, 2017, 2016, and 2015, respectively, were outstanding, but were not included in the computation of diluted net income per share because the effect of including such shares would have been anti-dilutive in the periods presented.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2017
Retirement Benefits [Abstract]
Employee Benefit Plans	EMPLOYEE BENEFIT PLANS The Company sponsors various retirement plans for its eligible U.S. and non-U.S. employees. For employees in the U.S., the Company maintains the Intuitive Surgical, Inc. 401(k) Plan (the “Plan”). As allowed under Section 401(k) of the Internal Revenue Code, the Plan provides tax-deferred salary contributions for eligible U.S. employees. The Plan allows employees to contribute up to 100% of their annual compensation to the Plan on a pre-tax and after-tax basis. Employee contributions are limited to a maximum annual amount as set periodically by the Internal Revenue Code. The Company matches 200% of employee contributions up to $1,500 per calendar year per person. All matching employer contributions vest immediately.

Selected Quarterly Data

12 Months Ended

Dec. 31, 2017

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Data



	Three Months Ended
	December 31, 2017			September 30, 2017			June 30, 2017			March 31, 2017
Revenue	$	892.4		$	806.1		$	756.2		$	674.2
Gross profit	$	633.3		$	566.8		$	527.9		$	466.1
Net income (loss) ⁽¹⁾⁽²⁾	$	(38.8	)	$	297.5		$	221.5		$	179.8
Net income (loss) per share:
Basic	$	(0.35	)	$	2.66		$	2.00		$	1.61
Diluted	$	(0.35	)	$	2.55		$	1.92		$	1.56

(1) Includes discrete tax benefits (expense) as follows:
Income tax (expense) related to the 2017 Tax Act	$	(317.8	)	$	—		$	—		$	—
Excess tax benefits related to share-based compensation arrangements	$	19.9		$	19.7		$	30.6		$	32.6
Certain one-time tax benefits	$	—		$	68.4		$	—		$	—
(2) Includes pre-tax litigation benefits (charges)	$	1.2		$	(9.7	)	$	4.5		$	(21.3	)
	Three Months Ended
	December 31, 2016			September 30, 2016			June 30, 2016			March 31, 2016
Revenue	$	756.9		$	682.9		$	670.1		$	594.5
Gross profit ⁽¹⁾	$	527.2		$	487.0		$	470.9		$	405.0
Net income ^(1)(2)(3)	$	204.0		$	211.0		$	184.5		$	136.4
Net income per share:
Basic	$	1.75		$	1.82		$	1.61		$	1.21
Diluted	$	1.71		$	1.77		$	1.57		$	1.18

(1) Includes pre-tax medical device excise tax refund benefit	$	—		$	7.1		$	—		$	—
(2) Includes discrete tax benefits as follows:
Audit settlement and expiration of the statutes of limitations in multiple jurisdictions	$	—		$	15.8		$	—		$	—
(3) Includes pre-tax litigation (charges)	$	(5.5	)	$	—		$	(4.4	)	$	(2.2	)

Valuation And Qualifying Accounts

12 Months Ended

Dec. 31, 2017

Valuation and Qualifying Accounts [Abstract]

Valuation And Qualifying Accounts



	Balance at Beginning of Year		Additions		Deductions ⁽¹⁾			Balance at End of Year
Allowance for doubtful accounts, loan credit losses, and sales returns
Year ended December 31, 2017	$	10.8	$	36.1	$	(32.3	)	$	14.6
Year ended December 31, 2016	$	9.4	$	24.6	$	(23.2	)	$	10.8
Year ended December 31, 2015	$	5.5	$	22.3	$	(18.4	)	$	9.4


(1)	Primarily represents products returned.

Summary Of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Concentrations of Credit Risk and Other Risks and Uncertainties

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity from date of purchase of 90 days or less to be cash equivalents.

Investments

Fair Value Measurements

Inventories

Inventory

Property, Plant and Equipment

Property, Plant, and Equipment



	Useful Lives
Building	Up to 30 years
Building improvements	Up to 15 years
Leasehold improvements	Lesser of useful life or term of lease
Equipment and furniture	5 years
Operating lease assets	Greater of lease term or 1 to 5 years
Computer and office equipment	3 years
Enterprise-wide software	5 years
Purchased software	Lesser of 3 years or life of license

Capitalized Software Costs for Internal Use

Goodwill and Intangible Assets

Impairment of Long-lived assets

Impairment of Long-lived Assets

Revenue Recognition

Leases

Allowance for Sales Returns and Doubtful Accounts

Share-Based Compensation

Risk-Free Interest Rate: The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.

Computation of Net Income per Share

Research and Development Expenses

Foreign Currency and Other Hedging Instruments

Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.

Income Taxes

Segments

Legal Contingencies

Recent Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

Adopted Accounting Pronouncement

Summary Of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Estimated Useful Lives Of The Assets



	Useful Lives
Building	Up to 30 years
Building improvements	Up to 15 years
Leasehold improvements	Lesser of useful life or term of lease
Equipment and furniture	5 years
Operating lease assets	Greater of lease term or 1 to 5 years
Computer and office equipment	3 years
Enterprise-wide software	5 years
Purchased software	Lesser of 3 years or life of license

The following table provides details of the property, plant, and equipment, net (in millions):



	December 31,
	2017			2016
Property, plant, and equipment, net:
Land	$	174.8		$	131.7
Building and building/leasehold improvements	230.5			199.5
Machinery and equipment	224.8			217.7
Operating lease assets	66.1			34.7
Computer and office equipment	44.8			41.3
Capitalized software	135.6			114.2
Construction-in-process	83.5			41.2
Gross property, plant, and equipment	960.1			780.3
Less: Accumulated depreciation*	(347.0		)	(321.9		)
Total property, plant, and equipment, net	$	613.1		$	458.4

*Accumulated depreciation associated with operating lease assets	$	(13.8	)	$	(6.8	)

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Summary of Cash and Available-For-Sale Securities



										Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2017
Cash	$	197.7	$	—	$	—		$	197.7	$	197.7	$	—	$	—
Level 1:
Money market funds	445.0		—		—			445.0		445.0		—		—
U.S. treasuries	1,029.1		—		(4.7		)	1,024.4		5.5		396.2		622.7
Subtotal	1,474.1		—		(4.7		)	1,469.4		450.5		396.2		622.7
Level 2:
Commercial paper	38.4		—		—			38.4		—		38.4		—
Corporate securities	946.6		0.2		(4.4		)	942.4		—		403.9		538.5
U.S. government agencies	901.3		—		(4.4		)	896.9		—		311.7		585.2
Non-U.S. government securities	2.5		—		—			2.5		—		2.5		—
Municipal securities	301.1		—		(1.9		)	299.2		—		159.7		139.5
Subtotal	2,189.9		0.2		(10.7		)	2,179.4		—		916.2		1,263.2
Total assets measured at fair value	$	3,861.7	$	0.2	$	(15.4	)	$	3,846.5	$	648.2	$	1,312.4	$	1,885.9



										Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2016
Cash	$	227.7	$	—	$	—		$	227.7	$	227.7	$	—	$	—
Level 1:
Money market funds	612.4		—		—			612.4		612.4		—		—
U.S. treasuries	625.9		0.1		(2.0		)	624.0		157.9		168.4		297.7
Subtotal	1,238.3		0.1		(2.0		)	1,236.4		770.3		168.4		297.7
Level 2:
Commercial paper	139.6		—		—			139.6		31.1		108.5		—
Corporate securities	1,471.8		0.7		(5.0		)	1,467.5		2.9		555.4		909.2
U.S. government agencies	938.7		0.5		(2.9		)	936.3		—		342.7		593.6
Non-U.S. government securities	18.5		—		—			18.5		—		16.0		2.5
Municipal securities	815.4		—		(3.5		)	811.9		4.6		327.0		480.3
Subtotal	3,384.0		1.2		(11.4		)	3,373.8		38.6		1,349.6		1,985.6
Total assets measured at fair value	$	4,850.0	$	1.3	$	(13.4	)	$	4,837.9	$	1,036.6	$	1,518.0	$	2,283.3

Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments



	Amortized Cost		Fair Value
Mature in less than one year	$	1,320.7	$	1,317.9
Mature in one to five years	1,898.3		1,885.9
Total	$	3,219.0	$	3,203.8

Schedule Of Available-For-Sale Investments With Unrealized Losses

The following tables present the breakdown of the available-for-sale investments with unrealized losses at December 31, 2017, and 2016 (in millions):



	Unrealized losses less than 12 months					Unrealized losses 12 months or greater					Total
December 31, 2017	Fair Value		Unrealized Losses			Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
Corporate securities	$	567.6	$	(2.1	)	$	277.0	$	(2.3	)	$	844.6	$	(4.4	)
U.S. treasuries	763.5		(2.5		)	206.2		(2.2		)	969.7		(4.7		)
U.S. government agencies	428.9		(1.3		)	345.5		(3.1		)	774.4		(4.4		)
Municipal securities	236.3		(1.3		)	51.7		(0.6		)	288.0		(1.9		)
	$	1,996.3	$	(7.2	)	$	880.4	$	(8.2	)	$	2,876.7	$	(15.4	)
December 31, 2016
Corporate securities	$	1,056.1	$	(5.0	)	$	—	$	—		$	1,056.1	$	(5.0	)
U.S. treasuries	357.1		(2.0		)	—		—			357.1		(2.0		)
U.S. government agencies	538.2		(2.9		)	—		—			538.2		(2.9		)
Municipal securities	728.8		(3.5		)	—		—			728.8		(3.5		)
	$	2,680.2	$	(13.4	)	$	—	$	—		$	2,680.2	$	(13.4	)

Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures

These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):



	Years Ended December 31,
	2017			2016			2015
Recognized gains (losses) in interest and other income, net	$	(9.2	)	$	6.4		$	7.0
Foreign exchange gains (losses) related to balance sheet re-measurement	$	9.7		$	(5.6	)	$	(7.9	)

Gross Notional Amounts for Outstanding Derivatives

Total gross notional amounts (in USD) for derivatives and aggregate gross fair value outstanding at the end of each period were as follows (in millions):



	Derivatives Designated as Hedging Instruments				Derivatives Not Designated as Hedging Instruments
	December 31, 2017		December 31, 2016		December 31, 2017		December 31, 2016
Notional amounts:
Forward contracts	$	128.5	$	109.7	$	168.4	$	143.7
Gross fair value recorded in:
Prepaid and other current assets	$	0.9	$	6.2	$	1.2	$	5.6
Other accrued liabilities	$	2.9	$	1.0	$	4.6	$	0.6

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Balance Sheet Details and Other Financial Information (Tables)

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Details of the Inventory Balance Sheet Item

The following table provides details of the inventories (in millions):



	December 31,
	2017		2016
Inventory:
Raw materials	$	80.9	$	54.8
Work-in-process	19.7		13.4
Finished goods	140.6		114.1
Total inventory	$	241.2	$	182.3

Details of the Property, Plant and Equipment, Net Balance Sheet Item



	Useful Lives
Building	Up to 30 years
Building improvements	Up to 15 years
Leasehold improvements	Lesser of useful life or term of lease
Equipment and furniture	5 years
Operating lease assets	Greater of lease term or 1 to 5 years
Computer and office equipment	3 years
Enterprise-wide software	5 years
Purchased software	Lesser of 3 years or life of license

The following table provides details of the property, plant, and equipment, net (in millions):



	December 31,
	2017			2016
Property, plant, and equipment, net:
Land	$	174.8		$	131.7
Building and building/leasehold improvements	230.5			199.5
Machinery and equipment	224.8			217.7
Operating lease assets	66.1			34.7
Computer and office equipment	44.8			41.3
Capitalized software	135.6			114.2
Construction-in-process	83.5			41.2
Gross property, plant, and equipment	960.1			780.3
Less: Accumulated depreciation*	(347.0		)	(321.9		)
Total property, plant, and equipment, net	$	613.1		$	458.4

*Accumulated depreciation associated with operating lease assets	$	(13.8	)	$	(6.8	)

Details of the Other Accrued Liabilities—Short Term Balance Sheet Item

The following table provides details of the other accrued liabilities—short term (in millions):



	December 31,
	2017		2016
Other accrued liabilities—short-term:
Taxes payable	$	63.1	$	40.4
Tolled product liability claims accrued	12.8		20.5
Other accrued liabilities	93.6		90.1
Total other accrued liabilities—short-term	$	169.5	$	151.0

Details of the Other Long-Term Liabilities Balance Sheet Item

The following table provides details of the other long-term liabilities (in millions):



	December 31,
	2017		2016
Other long-term liabilities:
Income taxes—long-term	$	286.8	$	84.9
Other long-term liabilities	40.3		27.7
Total other long-term liabilities	$	327.1	$	112.6

Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in millions):



	Years Ended December 31,
	2017		2016		2015
Income taxes paid	$	147.5	$	138.4	$	110.3
Supplemental non-cash investing activities:
Equipment transfers from inventory to property, plant, and equipment	$	65.8	$	39.3	$	26.7

Leases (Tables)

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Lease Receivables Relating to Sales-type Lease Arrangements

Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):



	December 31,
	2017			2016
Gross lease receivables	$	128.0		$	104.3
Unearned income	(5.0		)	(4.8		)
Allowance for credit loss	(0.9		)	(0.6		)
Net investment in sales-type leases	122.1			98.9
Reported as:
Prepaids and other current assets	41.9			29.8
Intangible and other assets, net	80.2			69.1
Total, net	$	122.1		$	98.9

Contractual Maturities of Gross Lease Receivables

Contractual maturities of gross lease receivables as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	44.4
2019	37.0
2020	26.6
2021	13.1
2022	6.4
2023 and thereafter	0.5
Total	$	128.0

Schedule Of Future Minimum Lease Receivables Under Operating Leases

The Company's operating lease terms are generally less than five years. Future minimum lease payments related to non-cancellable portion of operating leases as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	42.6
2019	41.2
2020	34.0
2021	19.5
2022	8.4
2023 and thereafter	0.7
Total	$	146.4

Future minimum lease commitments under the Company’s operating leases as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	8.2
2019	5.8
2020	4.4
2021	3.4
2022	3.0
2023 and thereafter	16.8
Total	$	41.6

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December 31, 2017, and 2016 (in millions):



	December 31, 2017							December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Patents and developed technology	$	156.0	$	(140.2	)	$	15.8	$	158.7	$	(141.6	)	$	17.1
Distribution rights and others	9.2		(9.2		)	—		9.2		(9.1		)	0.1
Customer relationships	28.6		(18.4		)	10.2		28.6		(14.3		)	14.3
Total intangible assets	$	193.8	$	(167.8	)	$	26.0	$	196.5	$	(165.0	)	$	31.5

Schedule Of Estimated Future Amortization Expense Of Intangible Assets

The estimated future amortization expense related to intangible assets as of December 31, 2017, is as follows (in millions):



Fiscal Year	Amount
2018	$	9.6
2019	4.6
2020	4.6
2021	3.4
2022	2.1
2023 and thereafter	1.7
Total	$	26.0

Commitments And Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Future Minimum Lease Commitments Under Operating Leases



Fiscal Year	Amount
2018	$	42.6
2019	41.2
2020	34.0
2021	19.5
2022	8.4
2023 and thereafter	0.7
Total	$	146.4

Future minimum lease commitments under the Company’s operating leases as of December 31, 2017, are as follows (in millions):



Fiscal Year	Amount
2018	$	8.2
2019	5.8
2020	4.4
2021	3.4
2022	3.0
2023 and thereafter	16.8
Total	$	41.6

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule Of Stock Repurchase Activities

The following table provides the stock repurchase activities during the years ended December 31, 2017, 2016, and 2015 (in millions, except per share amounts):



	Years Ended December 31,
	2017		2016		2015
Shares repurchased	7.3		0.2		1.1
Average price per share	$	310.32	$	201.70	$	167.41
Value of shares repurchased	$	2,274.0	$	42.5	$	183.7

Components of Accumulated Other Comprehensive Income (Loss), Net of Tax

The components of accumulated other comprehensive income (loss) net of tax, for the years ended December 31, 2017, and 2016, are as follows (in millions):



	Year Ended December 31, 2017
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for-Sale Securities			Foreign Currency Translation Gains (Losses)			Employee Benefit Plans			Total
Beginning balance	$	5.0		$	(8.6	)	$	(1.3	)	$	(4.0	)	$	(8.9	)
Other comprehensive income (loss) before reclassifications	(8.6		)	(2.7		)	3.6			(0.3		)	(8.0		)
Reclassified from accumulated other comprehensive loss	1.2			—			—			0.2			1.4
Net current-period other comprehensive income (loss)	(7.4		)	(2.7		)	3.6			(0.1		)	(6.6		)
Ending balance	$	(2.4	)	$	(11.3	)	$	2.3		$	(4.1	)	$	(15.5	)

	Year Ended December 31, 2016
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for-Sale Securities			Foreign Currency Translation Gains (Losses)			Employee Benefit Plans			Total
Beginning balance	$	1.5		$	(4.2	)	$	(3.3	)	$	(3.5	)	$	(9.5	)
Other comprehensive income (loss) before reclassifications	4.1			(4.6		)	2.0			(0.7		)	0.8
Reclassified from accumulated other comprehensive loss	(0.6		)	0.2			—			0.2			(0.2		)
Net current-period other comprehensive income (loss)	3.5			(4.4		)	2.0			(0.5		)	0.6
Ending balance	$	5.0		$	(8.6	)	$	(1.3	)	$	(4.0	)	$	(8.9	)

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary Of Stock Option Activity Under All Stock Plans

Option activity during fiscal 2017 under all the stock plans was as follows (in millions, except per share amounts):



	Stock Options Outstanding
	Number Outstanding		Weighted Average Exercise Price Per Share
Balance at December 31, 2016	9.3		$	148.36
Options granted	0.7		$	287.11
Options exercised	(2.7	)	$	140.70
Options forfeited/expired	(0.1	)	$	204.94
Balance at December 31, 2017	7.2		$	164.16

Summary Of Significant Ranges Of Outstanding And Exercisable Options

The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2017 (number of shares and aggregate intrinsic value in millions):



	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)		Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)
$31.96 - $113.73	1.6	2.3	$	92.43			1.6		$	92.43
$114.61 - $153.05	1.5	5.9	$	140.19			1.4		$	139.87
$155.57 - $172.44	1.6	5.4	$	169.56			1.4		$	169.67
$172.76 - $213.77	1.4	6.7	$	184.30			1.0		$	185.29
$213.97 - $391.04	1.1	9.1	$	266.31			0.3		$	250.46
Total	7.2	5.6	$	164.16	$	1,447.2	5.7	4.9	$	147.32	$	1,234.4


(1)	The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $364.94 at December 31, 2017, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.

Summary of RSU Activity

RSU activity for the year ended December 31, 2017, was as follows (in millions, except per share amounts):



	Shares		Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2016	1.8		$	174.72
Granted	1.0		$	249.34
Vested	(0.6	)	$	171.42
Forfeited	(0.1	)	$	204.08
Unvested balance at December 31, 2017	2.1		$	209.55

Summary Of Share-Based Compensation Expense

The following table summarizes share-based compensation expense (in millions):



	Years Ended December 31,
	2017		2016		2015
Cost of sales—products	$	28.1	$	25.2	$	22.8
Cost of sales—services	14.0		12.4		12.9
Total cost of sales	42.1		37.6		35.7
Selling, general and administrative	111.8		97.4		94.7
Research and development	56.0		43.0		37.7
Share-based compensation expense before income taxes	209.9		178.0		168.1
Income tax effect	49.2		56.1		51.8
Share-based compensation expense after income taxes	$	160.7	$	121.9	$	116.3

Schedule Of Estimated Fair Values Of The Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions and Fair Value of RSUs

The weighted average estimated fair values of stock options, the rights to acquire stock granted, and RSUs, as well as the weighted average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December 31, 2017, 2016, and 2015, were as follows:



	Years Ended December 31,
STOCK OPTION PLANS	2017			2016			2015
Risk-free interest rate	1.8		%	1.1		%	1.6		%
Expected term (years)	4.1			4.2			4.3
Volatility	25		%	26		%	28		%
Fair value at grant date	$	67.03		$	47.06		$	43.82
EMPLOYEE STOCK PURCHASE PLAN
Risk-free interest rate	1.2		%	0.6		%	0.4		%
Expected term (years)	1.2			1.2			1.2
Volatility	28		%	30		%	31		%
Fair value at grant date	$	79.77		$	57.57		$	48.91
RESTRICTED STOCK UNITS
Fair value at grant date	$	249.34		$	184.59		$	170.64

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule Of Income Before Provision For Income Taxes

Income before provision for income taxes for the years ended December 31, 2017, 2016, and 2015, consisted of the following (in millions):



	Years Ended December 31,
	2017		2016		2015
U.S.	$	765.0	$	653.0	$	425.1
Foreign	331.5		327.8		333.4
Total income before provision for income taxes	$	1,096.5	$	980.8	$	758.5

Schedule Of Provision For Income Taxes

The provision for income taxes for the years ended December 31, 2017, 2016, and 2015, consisted of the following (in millions):



	Years Ended December 31,
	2017			2016		2015
Current
Federal	$	352.1		$	207.0	$	148.7
State	13.0			13.4		8.4
Foreign	8.7			5.4		7.6
	$	373.8		$	225.8	$	164.7
Deferred
Federal	$	65.5		$	18.3	$	7.5
State	(0.4		)	0.6		0.5
Foreign	(2.4		)	0.2		(3.0		)
	$	62.7		$	19.1	$	5.0
Total income tax expense	$	436.5		$	244.9	$	169.7

Schedule Of Income Tax Difference From The Statutory Rate



	Years Ended December 31,
	2017			2016			2015
Federal tax at statutory rate	$	383.8		$	343.3		$	265.5
Increase (reduction) in tax resulting from:
State taxes, net of federal benefits	16.0			14.0			8.9
Foreign rate differential	(107.3		)	(86.2		)	(67.4		)
Research and development credit	(15.3		)	(7.8		)	(6.4		)
Share-based compensation not benefited	10.8			3.6			6.9
Domestic production activities deduction	(7.9		)	(8.0		)	(5.3		)
Reversal of unrecognized tax benefits	(62.4		)	(15.8		)	(6.4		)
Reversal of share-based compensation from intercompany charges	—			—			(25.0		)
Tax Cuts and Jobs Act impact	317.8			—			—
Excess tax benefits	(102.8		)	—			—
Other	3.8			1.8			(1.1		)
Total income tax expense	$	436.5		$	244.9		$	169.7

Schedule Of Deferred Tax Assets



	December 31,
	2017			2016
Deferred tax assets:
Share-based compensation expense	$	79.1		$	122.2
Expenses deducted in later years for tax purposes	29.7			47.4
Research and other credits	27.5			15.6
Other	10.5			9.8
Gross deferred tax assets	$	146.8		$	195.0
Valuation allowance	(29.4		)	(17.2		)
Deferred tax assets	$	117.4		$	177.8
Deferred tax liabilities:
Fixed assets	$	(26.3	)	$	(25.2	)
Intangible assets	(3.6		)	(2.3		)
Other	(0.2		)	(0.2		)
Deferred tax liabilities	$	(30.1	)	$	(27.7	)
Net deferred tax assets	$	87.3		$	150.1

Schedule Of Gross Unrecognized Income Tax Benefits

A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December 31, 2017, 2016, and 2015, are as follows (in millions):



	Years Ended December 31,
	2017			2016			2015
Beginning balance	$	106.0		$	92.4		$	75.5
Increases related to tax positions taken during the current year	21.1			29.9			28.9
Increases related to tax positions taken during a prior year	—			—			0.3
Decreases related to tax positions taken during a prior year	(46.5		)	(0.5		)	—
Decreases related to settlements with tax authorities	(0.5		)	—			(11.4		)
Decreases related to expiration of statute of limitations	(14.7		)	(15.8		)	(0.9		)
Ending balance	$	65.4		$	106.0		$	92.4

Net Income Per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Computation Of Basic And Diluted Net Income Per Share

The following table presents the computation of basic and diluted net income per share (in millions, except per share amounts):



	Years Ended December 31,
	2017		2016		2015
Numerator:
Net income	$	660.0	$	735.9	$	588.8
Denominator:
Weighted-average shares outstanding in basic calculation	111.7		114.9		111.3
Add: dilutive effect of potential common shares	4.6		3.0		2.4
Weighted-average shares used in computing diluted net income per share	116.3		117.9		113.7
Net income per share:
Basic	$	5.91	$	6.40	$	5.29
Diluted	$	5.67	$	6.24	$	5.18

Selected Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2017

Selected Quarterly Financial Information [Abstract]

Schedule Of Selected Quarterly Data



	Three Months Ended
	December 31, 2017			September 30, 2017			June 30, 2017			March 31, 2017
Revenue	$	892.4		$	806.1		$	756.2		$	674.2
Gross profit	$	633.3		$	566.8		$	527.9		$	466.1
Net income (loss) ⁽¹⁾⁽²⁾	$	(38.8	)	$	297.5		$	221.5		$	179.8
Net income (loss) per share:
Basic	$	(0.35	)	$	2.66		$	2.00		$	1.61
Diluted	$	(0.35	)	$	2.55		$	1.92		$	1.56

(1) Includes discrete tax benefits (expense) as follows:
Income tax (expense) related to the 2017 Tax Act	$	(317.8	)	$	—		$	—		$	—
Excess tax benefits related to share-based compensation arrangements	$	19.9		$	19.7		$	30.6		$	32.6
Certain one-time tax benefits	$	—		$	68.4		$	—		$	—
(2) Includes pre-tax litigation benefits (charges)	$	1.2		$	(9.7	)	$	4.5		$	(21.3	)
	Three Months Ended
	December 31, 2016			September 30, 2016			June 30, 2016			March 31, 2016
Revenue	$	756.9		$	682.9		$	670.1		$	594.5
Gross profit ⁽¹⁾	$	527.2		$	487.0		$	470.9		$	405.0
Net income ^(1)(2)(3)	$	204.0		$	211.0		$	184.5		$	136.4
Net income per share:
Basic	$	1.75		$	1.82		$	1.61		$	1.21
Diluted	$	1.71		$	1.77		$	1.57		$	1.18

(1) Includes pre-tax medical device excise tax refund benefit	$	—		$	7.1		$	—		$	—
(2) Includes discrete tax benefits as follows:
Audit settlement and expiration of the statutes of limitations in multiple jurisdictions	$	—		$	15.8		$	—		$	—
(3) Includes pre-tax litigation (charges)	$	(5.5	)	$	—		$	(4.4	)	$	(2.2	)

Summary Of Significant Accounting Policies - Additional Information (Detail)		3 Months Ended								12 Months Ended
	Oct. 05, 2017 $ / shares	Dec. 31, 2017 USD ($) $ / shares	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) customer segment $ / shares	Dec. 31, 2016 USD ($) customer $ / shares	Dec. 31, 2015 USD ($) customer	Jan. 01, 2018 USD ($)
Accounting Policies [Abstract]
Common stock split ratio (shares)	3
Common stock, par value (usd per share) \| $ / shares	$ 0.001	$ 0.001				$ 0.001				$ 0.001	$ 0.001
Summary Of Significant Accounting Policies [Line Items]
Other-than-temporary impairment losses										$ 0	$ 0	$ 0
Depreciation expense										$ 82,100,000	70,700,000	61,100,000
Number of operating segments \| segment										1
Impairment of goodwill										$ 0
System sales arrangement, free service period										1 year
System sales arrangement, additional period of service										4 years
Operating lease revenue										$ 25,900,000	16,600,000	7,000,000
Market-based implied volatility (period)										1 year
Market-based implied volatility (percent)										100.00%
Cash flow hedges de-designated (period)										2 months
Likelihood of tax benefits being realized upon ultimate settlement										50.00%
Total revenue		$ 892,400,000	$ 806,100,000	$ 756,200,000	$ 674,200,000	$ 756,900,000	$ 682,900,000	$ 670,100,000	$ 594,500,000	$ 3,128,900,000	2,704,400,000	2,384,400,000
Service										581,800,000	517,000,000	464,800,000
Product										2,547,100,000	2,187,400,000	1,919,600,000
Operating expenses										1,139,500,000	944,900,000	837,900,000
Retained earnings		61,400,000				$ 1,574,900,000				61,400,000	1,574,900,000
Excess tax benefits related to share-based compensation arrangements		$ 19,900,000	$ 19,700,000	$ 30,600,000	$ 32,600,000					$ 102,800,000	0	0
Excess tax benefits related to share-based compensation arrangements, percent reduction										9.40%
Net cash provided by (used in) financing activities										$ (1,913,100,000)	514,400,000	159,100,000
Net cash provided by operating activities										1,143,900,000	1,087,000,000	806,200,000
ASU No. 2014-09
Summary Of Significant Accounting Policies [Line Items]
Product										9,000,000	6,000,000
ASU No. 2014-09 \| Pro forma
Summary Of Significant Accounting Policies [Line Items]
Total revenue										9,000,000	2,000,000
Service										(9,000,000)	(6,000,000)
Operating expenses										$ (1,000,000)	(2,000,000)
ASU 2016-16
Summary Of Significant Accounting Policies [Line Items]
Deferred tax assets													$ 390,000,000
ASU 2016-16 \| Retained Earnings
Summary Of Significant Accounting Policies [Line Items]
Catch-up adjustment to retained earnings													$ 390,000,000
ASU No. 2016-09
Summary Of Significant Accounting Policies [Line Items]
Net cash provided by (used in) financing activities											(44,100,000)	(34,300,000)
Net cash provided by operating activities											44,100,000	34,300,000
Enterprise-wide software
Summary Of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives										5 years
Internal use software
Summary Of Significant Accounting Policies [Line Items]
Capitalized computer software, gross										$ 22,400,000	$ 11,800,000	$ 14,800,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible asset										1 year
Sales-type leases term										24 months
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible asset										9 years
Sales-type leases term										84 months
Derivative, term of contract										12 months
Maximum \| Internal use software
Summary Of Significant Accounting Policies [Line Items]
Property, plant and equipment, estimated useful lives										5 years
United States
Summary Of Significant Accounting Policies [Line Items]
Long-lived assets, percent										88.00%	86.00%
Accounts Receivable \| United States
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage										69.00%	73.00%
Total Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers representing more than 10% of total revenue \| customer										0	0	0
Total Revenue \| United States
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage										73.00%	72.00%	71.00%
Total Revenue \| International
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage										27.00%	28.00%	29.00%

Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Detail)	12 Months Ended
	Dec. 31, 2017
Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	Up to 30 years
Property, plant and equipment, estimated useful lives	30 years
Building improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	Up to 15 years
Property, plant and equipment, estimated useful lives	15 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	Lesser of useful life or term of lease
Equipment and furniture
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	5 years
Operating lease assets
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	Greater of lease term or 1 to 5 years
Operating lease assets \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	5 years
Operating lease assets \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	1 year
Computer and office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	3 years
Enterprise-wide software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	5 years
Purchased software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	Lesser of 3 years or life of license
Property, plant and equipment, estimated useful lives	3 years

Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 3,861.7	$ 4,850.0
Gross Unrealized Gains	0.2	1.3
Gross Unrealized Losses	(15.4)	(13.4)
Fair Value	3,846.5	4,837.9
Cash and Cash Equivalents	648.2	1,036.6	$ 714.6	$ 600.3
Short-term Investments	1,312.4	1,518.0
Long-term Investments	1,885.9	2,283.3
Cash
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	197.7	227.7
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	197.7	227.7
Cash and Cash Equivalents	197.7	227.7
Short-term Investments	0.0	0.0
Long-term Investments	0.0	0.0
Level 1
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,474.1	1,238.3
Gross Unrealized Gains	0.0	0.1
Gross Unrealized Losses	(4.7)	(2.0)
Fair Value	1,469.4	1,236.4
Cash and Cash Equivalents	450.5	770.3
Short-term Investments	396.2	168.4
Long-term Investments	622.7	297.7
Level 1 \| Money market funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	445.0	612.4
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	445.0	612.4
Cash and Cash Equivalents	445.0	612.4
Short-term Investments	0.0	0.0
Long-term Investments	0.0	0.0
Level 1 \| U.S. treasuries
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,029.1	625.9
Gross Unrealized Gains	0.0	0.1
Gross Unrealized Losses	(4.7)	(2.0)
Fair Value	1,024.4	624.0
Cash and Cash Equivalents	5.5	157.9
Short-term Investments	396.2	168.4
Long-term Investments	622.7	297.7
Level 2
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,189.9	3,384.0
Gross Unrealized Gains	0.2	1.2
Gross Unrealized Losses	(10.7)	(11.4)
Fair Value	2,179.4	3,373.8
Cash and Cash Equivalents	0.0	38.6
Short-term Investments	916.2	1,349.6
Long-term Investments	1,263.2	1,985.6
Level 2 \| Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	38.4	139.6
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	38.4	139.6
Cash and Cash Equivalents	0.0	31.1
Short-term Investments	38.4	108.5
Long-term Investments	0.0	0.0
Level 2 \| Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	946.6	1,471.8
Gross Unrealized Gains	0.2	0.7
Gross Unrealized Losses	(4.4)	(5.0)
Fair Value	942.4	1,467.5
Cash and Cash Equivalents	0.0	2.9
Short-term Investments	403.9	555.4
Long-term Investments	538.5	909.2
Level 2 \| U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	901.3	938.7
Gross Unrealized Gains	0.0	0.5
Gross Unrealized Losses	(4.4)	(2.9)
Fair Value	896.9	936.3
Cash and Cash Equivalents	0.0	0.0
Short-term Investments	311.7	342.7
Long-term Investments	585.2	593.6
Level 2 \| Non-U.S. government securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2.5	18.5
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	2.5	18.5
Cash and Cash Equivalents	0.0	0.0
Short-term Investments	2.5	16.0
Long-term Investments	0.0	2.5
Level 2 \| Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	301.1	815.4
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	(1.9)	(3.5)
Fair Value	299.2	811.9
Cash and Cash Equivalents	0.0	4.6
Short-term Investments	159.7	327.0
Long-term Investments	$ 139.5	$ 480.3

Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Detail) $ in Millions	Dec. 31, 2017 USD ($)
Amortized Cost
Mature in less than one year	$ 1,320.7
Mature in one to five years	1,898.3
Total	3,219.0
Fair Value
Mature in less than one year	1,317.9
Mature in one to five years	1,885.9
Total	$ 3,203.8

Financial Instruments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Net unrealized losses on investments	$ (11.3)	$ (8.6)
Net gains reclassified to revenue	$ (2.9)	$ 0.9	$ 7.2

Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	$ 1,996.3	$ 2,680.2
Unrealized losses less than 12 months	(7.2)	(13.4)
Unrealized losses 12 months or greater Fair Value	880.4	0.0
Unrealized losses 12 months or greater	(8.2)	0.0
Total Fair Value	2,876.7	2,680.2
Total Unrealized Losses	(15.4)	(13.4)
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	567.6	1,056.1
Unrealized losses less than 12 months	(2.1)	(5.0)
Unrealized losses 12 months or greater Fair Value	277.0	0.0
Unrealized losses 12 months or greater	(2.3)	0.0
Total Fair Value	844.6	1,056.1
Total Unrealized Losses	(4.4)	(5.0)
U.S. treasuries
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	763.5	357.1
Unrealized losses less than 12 months	(2.5)	(2.0)
Unrealized losses 12 months or greater Fair Value	206.2	0.0
Unrealized losses 12 months or greater	(2.2)	0.0
Total Fair Value	969.7	357.1
Total Unrealized Losses	(4.7)	(2.0)
U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	428.9	538.2
Unrealized losses less than 12 months	(1.3)	(2.9)
Unrealized losses 12 months or greater Fair Value	345.5	0.0
Unrealized losses 12 months or greater	(3.1)	0.0
Total Fair Value	774.4	538.2
Total Unrealized Losses	(4.4)	(2.9)
Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	236.3	728.8
Unrealized losses less than 12 months	(1.3)	(3.5)
Unrealized losses 12 months or greater Fair Value	51.7	0.0
Unrealized losses 12 months or greater	(0.6)	0.0
Total Fair Value	288.0	728.8
Total Unrealized Losses	$ (1.9)	$ (3.5)

Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange gains (losses) related to balance sheet re-measurement	$ 9.7	$ (5.6)	$ (7.9)
Foreign Exchange Forward \| Other income \| Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized gains (losses) in interest and other income, net	$ (9.2)	$ 6.4	$ 7.0

Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Detail) - Forward contracts - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Derivatives Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	$ 128.5	$ 109.7
Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	168.4	143.7
Prepaid and other current assets \| Derivatives Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	0.9	6.2
Prepaid and other current assets \| Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	1.2	5.6
Other accrued liabilities \| Derivatives Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	2.9	1.0
Other accrued liabilities \| Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	$ 4.6	$ 0.6

Balance Sheet Details and Other Financial Information - Inventory (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Inventory:
Raw materials	$ 80.9	$ 54.8
Work-in-process	19.7	13.4
Finished goods	140.6	114.1
Total inventory	$ 241.2	$ 182.3

Balance Sheet Details and Other Financial Information - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Property, plant, and equipment, net:
Land	$ 174.8	$ 131.7
Building and building/leasehold improvements	230.5	199.5
Machinery and equipment	224.8	217.7
Operating lease assets	66.1	34.7
Computer and office equipment	44.8	41.3
Capitalized software	135.6	114.2
Construction-in-process	83.5	41.2
Gross property, plant, and equipment	960.1	780.3
Less: Accumulated depreciation	(347.0)	(321.9)
Total property, plant, and equipment, net	613.1	458.4
Accumulated depreciation associated with operating lease assets	$ (13.8)	$ (6.8)

Balance Sheet Details and Other Financial Information - Other Accrued Liabilities—Short Term (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Taxes payable	$ 63.1	$ 40.4
Tolled product liability claims accrued	12.8	20.5
Other accrued liabilities	93.6	90.1
Total other accrued liabilities—short-term	$ 169.5	$ 151.0

Balance Sheet Details and Other Financial Information - Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Income taxes—long-term	$ 286.8	$ 84.9
Other long-term liabilities	40.3	27.7
Total other long-term liabilities	$ 327.1	$ 112.6

Balance Sheet Details and Other Financial Information - Supplemental Cash Flow Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Income taxes paid	$ 147.5	$ 138.4	$ 110.3
Supplemental non-cash investing activities:
Equipment transfers from inventory to property, plant, and equipment	$ 65.8	$ 39.3	$ 26.7

Leases - Lease Receivables (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Leases [Abstract]
Gross lease receivables	$ 128.0	$ 104.3
Unearned income	(5.0)	(4.8)
Allowance for credit loss	(0.9)	(0.6)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net investment in sales-type leases	122.1	98.9
Capital Leases, Future Minimum Payments Receivable, Fiscal Year Maturity [Abstract]
2018	44.4
2019	37.0
2020	26.6
2021	13.1
2022	6.4
2023 and thereafter	0.5
Total	128.0
Prepaid and other current assets
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net investment in sales-type leases	41.9	29.8
Intangible and other assets, net
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net investment in sales-type leases	$ 80.2	$ 69.1

Leases - Operating Leases (Detail) $ in Millions	Dec. 31, 2017 USD ($)
Leases [Abstract]
2018	$ 42.6
2019	41.2
2020	34.0
2021	19.5
2022	8.4
2023 and thereafter	0.7
Total	$ 146.4

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to intangible assets	$ 12.9	$ 18.2	$ 24.4

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 193.8	$ 196.5
Accumulated Amortization	(167.8)	(165.0)
Net Carrying Amount	26.0	31.5
Patents and developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	156.0	158.7
Accumulated Amortization	(140.2)	(141.6)
Net Carrying Amount	15.8	17.1
Distribution rights and others
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	9.2	9.2
Accumulated Amortization	(9.2)	(9.1)
Net Carrying Amount	0.0	0.1
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	28.6	28.6
Accumulated Amortization	(18.4)	(14.3)
Net Carrying Amount	$ 10.2	$ 14.3

Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 9.6
2019	4.6
2020	4.6
2021	3.4
2022	2.1
2023 and thereafter	1.7
Net Carrying Amount	$ 26.0	$ 31.5

Commitments And Contingencies - Schedule Of Future Minimum Lease Commitments Under Operating Leases (Detail) $ in Millions	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 8.2
2019	5.8
2020	4.4
2021	3.4
2022	3.0
2023 and thereafter	16.8
Total	$ 41.6

Commitments and Contingencies - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) state patient Defendant	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating lease maximum term (in years)	15 years
Other commitments	$ 478.1
Pre-tax settlement charges	11.7
Commitments And Contingencies [Line Items]
Accrued liabilities, product liability claims	$ 12.8	$ 20.5
da Vinci Surgical System Product Liability Matters
Commitments And Contingencies [Line Items]
Number of individual defendants involved in lawsuit \| Defendant	43
Number of patients on behalf of which damages are sought \| patient	55
Number of Surgeries Performed with da Vinci Surgical System in United States \| state	22
Estimated cost of settling product liability claims	$ 16.3	$ 8.3	$ 13.8

Stockholders' Equity - Additional Information (Detail) - USD ($) shares in Millions			12 Months Ended
	Dec. 07, 2017	Jan. 27, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 24, 2017
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, remaining authorized amount			$ 717,500,000
Repurchase of common stock			$ 2,274,000,000	$ 42,500,000	$ 183,700,000
Shares repurchased (shares)			7.3	0.2	1.1
Aggregate reduction in common stock and additional paid-in capital during stock repurchases			$ 152,000,000	$ 4,100,000	$ 16,300,000
Amount charged to retained earnings during stock repurchases			2,122,000,000	$ 38,400,000	$ 167,400,000
Goldman \| ASR Program
Equity, Class of Treasury Stock [Line Items]
Repurchase of common stock	$ 274,000,000	$ 2,000,000,000
Shares repurchased (shares)		7.3
Payment amount divided by closing price, percent		80.00%
Common stock
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount			6,200,000,000.0
Stock repurchase program, increased to authorized amount			$ 3,000,000,000
Common stock \| Goldman \| ASR Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount						$ 2,000,000,000.0

Stockholders' Equity - Schedule Of Stock Repurchase Activities (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Shares repurchased (shares)	7.3	0.2	1.1
Average price per share (usd per share)	$ 310.32	$ 201.70	$ 167.41
Value of shares repurchased	$ 2,274.0	$ 42.5	$ 183.7

Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 5,777.8
Other comprehensive income (loss) before reclassifications	(8.0)	$ 0.8
Reclassified from accumulated other comprehensive loss	1.4	(0.2)
Other comprehensive gains (losses)	(6.6)	0.6	$ (4.4)
Ending balance	4,725.2	5,777.8
Gains (Losses) on Hedge Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	5.0	1.5
Other comprehensive income (loss) before reclassifications	(8.6)	4.1
Reclassified from accumulated other comprehensive loss	1.2	(0.6)
Other comprehensive gains (losses)	(7.4)	3.5
Ending balance	(2.4)	5.0	1.5
Unrealized Gains (Losses) on Available-for-Sale Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(8.6)	(4.2)
Other comprehensive income (loss) before reclassifications	(2.7)	(4.6)
Reclassified from accumulated other comprehensive loss	0.0	0.2
Other comprehensive gains (losses)	(2.7)	(4.4)
Ending balance	(11.3)	(8.6)	(4.2)
Foreign Currency Translation Gains (Losses)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(1.3)	(3.3)
Other comprehensive income (loss) before reclassifications	3.6	2.0
Reclassified from accumulated other comprehensive loss	0.0	0.0
Other comprehensive gains (losses)	3.6	2.0
Ending balance	2.3	(1.3)	(3.3)
Employee Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(4.0)	(3.5)
Other comprehensive income (loss) before reclassifications	(0.3)	(0.7)
Reclassified from accumulated other comprehensive loss	0.2	0.2
Other comprehensive gains (losses)	(0.1)	(0.5)
Ending balance	(4.1)	(4.0)	(3.5)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(8.9)	(9.5)
Other comprehensive gains (losses)	(6.6)	0.6	(4.4)
Ending balance	$ (15.5)	$ (8.9)	$ (9.5)

Share-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) period $ / shares shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares	Apr. 30, 2017 shares	Mar. 31, 2017 shares	Apr. 30, 2015 shares	Mar. 31, 2015 shares	Oct. 31, 2009 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options exercised under stock option plans \| $	$ 379.9	$ 273.3	$ 196.5
Cash received from option exercises and employee stock purchase plans \| $	$ 415.5	580.9	361.1
Number of options vested and expected to vest	7,100,000
Weighted average remaining contractual life of shares vested and expected to vest, years	5 years 6 months 25 days
Aggregate intrinsic value of shares vested and expected to vest \| $	$ 1,429.6
Options vested and expected to vest, weighted-average exercise price per share \| $ / shares	$ 162.50
Share-based compensation charges, income tax effect \| $	$ 49.2	56.1	51.8
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options \| $	118.9
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense \| $	$ 278.9
Weighted average period unrecognized compensation expenses are expected to be recognized, years	2 years 4 months 24 days
Expected to vest (in shares)	1,900,000
Aggregate intrinsic value \| $	$ 700.1
Canceled (shares)	100,000
Vested in period, aggregate fair value \| $	$ 144.2	$ 65.3	$ 29.5
Restricted Stock Units (RSUs) \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Share based vesting period	4 years
Restricted Stock Units (RSUs) \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period	1 year
Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon six months of service	12.50%
Percentage vesting per month after six months of service	2.0833%
New Hire Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon one year of service	25.00%
Percentage vesting per month after one year	2.0833%
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares were reserved for future issuance (shares)	1,600,000
Minimum hours employed per week	20 hours
Minimum months employed per year	5 months
Maximum percentage of employees on stockholders to participate in ESPP	5.00%
Percentage of employee payroll deduction under the stock plan, maximum	15.00%
Duration for each offering period	24 months
Number of shorter purchase periods that each offering period is divided into \| period	4
Duration of each shorter offering period	6 months
Discount on fair market value on the offering date	85.00%
Discount on fair market value on the purchase date	85.00%
Period of look-back that could cause offering period to reset	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				7,590,315	6,090,315
Employee stock purchase plan, shares issued	200,000	200,000	300,000
Employee stock purchase plan, value of shares issued \| $	$ 38.3	$ 32.5	$ 31.2
Total unrecognized compensation expense \| $	$ 18.4
Weighted average period unrecognized compensation expenses are expected to be recognized, years	1 year 6 months
Nonvested Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense \| $	$ 69.9
Weighted average period unrecognized compensation expenses are expected to be recognized, years	2 years 3 months 18 days
Initial RSU grants \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.3333%
Share based vesting period		3 years
February Grant \| Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon six months of service	12.50%
Percentage vesting per month after six months of service	2.0833%
August Grant \| Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting at the end of one month	14.5833%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	2.0833%
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Number of shares of common stock reserved for issuance (shares)				24,450,000	21,150,000
Shares were reserved for future issuance (shares)	6,200,000
2010 Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares were reserved for future issuance (shares)	2,700,000
2010 Plan \| February Grant \| Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period	4 years
2010 Plan \| August Grant \| Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period	3 years 6 months
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Number of shares of common stock reserved for issuance (shares)						4,365,000	3,465,000
Shares were reserved for future issuance (shares)	43,000
2000 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Minimum exercise price of NSOs, percentage of fair value	85.00%
2000 Non-Employee Directors' Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Number of shares of common stock reserved for issuance (shares)								450,000
Shares were reserved for future issuance (shares)	100,000
2000 Non-Employee Directors' Stock Option Plan \| Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period	1 year
2000 Non-Employee Directors' Stock Option Plan \| Initial Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon one year of service		33.3333%
Percentage vesting per month after one year		2.7778%
Stock options granted initial vesting period, years		3 years

Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Detail) shares in Millions	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Number Outstanding
Beginning balance (shares) \| shares	9.3
Options granted (shares) \| shares	0.7
Options exercised (shares) \| shares	(2.7)
Options forfeited/expired (shares) \| shares	(0.1)
Ending balance (shares) \| shares	7.2
Weighted Average Exercise Price Per Share
Beginning balance (usd per share) \| $ / shares	$ 148.36
Options granted (usd per share) \| $ / shares	287.11
Options exercised (usd per share) \| $ / shares	140.70
Options forfeited/expired (usd per share) \| $ / shares	204.94
Ending balance (usd per share) \| $ / shares	$ 164.16

Share-Based Compensation - Outstanding and Exercisable Options Ranges (Detail) $ / shares in Units, shares in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Shares \| shares	7.2
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 164.16
Options Outstanding, Aggregate Intrinsic Value \| $	$ 1,447,200,000
Options Exercisable, Number of Shares \| shares	5.7
Options Exercisable, Weighted Average Remaining Contractual Life	4 years 10 months 24 days
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 147.32
Options Exercisable, Aggregate Intrinsic Value \| $	$ 1,234,400,000
Closing stock price (usd per share) \| $	$ 364.94
Exercise Price Range 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	$ 31.96
Range of Exercise Prices, maximum (usd per share)	$ 113.73
Options Outstanding, Number of Shares \| shares	1.6
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 92.43
Options Exercisable, Number of Shares \| shares	1.6
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 92.43
Exercise Price Range 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	114.61
Range of Exercise Prices, maximum (usd per share)	$ 153.05
Options Outstanding, Number of Shares \| shares	1.5
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 10 months 24 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 140.19
Options Exercisable, Number of Shares \| shares	1.4
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 139.87
Exercise Price Range 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	155.57
Range of Exercise Prices, maximum (usd per share)	$ 172.44
Options Outstanding, Number of Shares \| shares	1.6
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 169.56
Options Exercisable, Number of Shares \| shares	1.4
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 169.67
Exercise Price Range 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	172.76
Range of Exercise Prices, maximum (usd per share)	$ 213.77
Options Outstanding, Number of Shares \| shares	1.4
Options Outstanding, Weighted Average Remaining Contractual Life	6 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 184.30
Options Exercisable, Number of Shares \| shares	1.0
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 185.29
Exercise Price Range 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	213.97
Range of Exercise Prices, maximum (usd per share)	$ 391.04
Options Outstanding, Number of Shares \| shares	1.1
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 266.31
Options Exercisable, Number of Shares \| shares	0.3
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 250.46

Share-Based Compensation - Summary of RSU Activity (Detail) - Restricted Stock Units (RSUs) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shares
Unvested beginning balance (shares)	1.8
Granted (shares)	1.0
Vested (shares)	(0.6)
Canceled (shares)	(0.1)
Unvested ending balance (shares)	2.1	1.8
Weighted Average Grant Date Fair Value
Unvested beginning balance (usd per share)	$ 174.72
Fair value at grant date (usd per share)	249.34	$ 184.59	$ 170.64
Vested (usd per share)	171.42
Canceled (usd per share)	204.08
Unvested ending balance (usd per share)	$ 209.55	$ 174.72

Share-Based Compensation - Share-Based Compensation Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 209.9	$ 178.0	$ 168.1
Income tax effect	49.2	56.1	51.8
Share-based compensation expense after income taxes	160.7	121.9	116.3
Total cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	42.1	37.6	35.7
Total cost of sales \| Cost of sales—products
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	28.1	25.2	22.8
Total cost of sales \| Cost of sales—services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	14.0	12.4	12.9
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	111.8	97.4	94.7
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 56.0	$ 43.0	$ 37.7

Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
STOCK OPTION PLANS
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.80%	1.10%	1.60%
Expected term (years)	4 years 1 month 6 days	4 years 2 months	4 years 3 months 18 days
Volatility (percent)	25.00%	26.00%	28.00%
Weighted average fair value at grant date (usd per share)	$ 67.03	$ 47.06	$ 43.82
EMPLOYEE STOCK PURCHASE PLAN
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.20%	0.60%	0.40%
Expected term (years)	1 year 2 months 12 days	1 year 2 months 12 days	1 year 2 months 12 days
Volatility (percent)	28.00%	30.00%	31.00%
Weighted average fair value at grant date (usd per share)	$ 79.77	$ 57.57	$ 48.91
RESTRICTED STOCK UNITS
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value at grant date (usd per share)	$ 249.34	$ 184.59	$ 170.64

Income Taxes - Schedule Of Income Before Provision For Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income before provision for income taxes, U.S.	$ 765.0	$ 653.0	$ 425.1
Income before provision for income taxes, Foreign	331.5	327.8	333.4
Income before taxes	$ 1,096.5	$ 980.8	$ 758.5

Income Taxes - Schedule Of Provision For Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current income taxes, Federal	$ 352.1	$ 207.0	$ 148.7
Current income taxes, State	13.0	13.4	8.4
Current income taxes, Foreign	8.7	5.4	7.6
Current income taxes	373.8	225.8	164.7
Deferred income taxes, Federal	65.5	18.3	7.5
Deferred income taxes, State	(0.4)	0.6	0.5
Deferred income taxes, Foreign	(2.4)	0.2	(3.0)
Deferred income taxes	62.7	19.1	5.0
Total income tax expense	$ 436.5	$ 244.9	$ 169.7

Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Detail) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal tax at statutory rate					$ 383.8	$ 343.3	$ 265.5
State taxes, net of federal benefits					16.0	14.0	8.9
Foreign rate differential					(107.3)	(86.2)	(67.4)
Research and development credit					(15.3)	(7.8)	(6.4)
Share-based compensation not benefited					10.8	3.6	6.9
Domestic production activities deduction					(7.9)	(8.0)	(5.3)
Reversal of unrecognized tax benefits					(62.4)	(15.8)	(6.4)
Reversal of share-based compensation from intercompany charges					0.0	0.0	(25.0)
Tax Cuts and Jobs Act impact					317.8	0.0	0.0
Excess tax benefits	$ (19.9)	$ (19.7)	$ (30.6)	$ (32.6)	(102.8)	0.0	0.0
Other					3.8	1.8	(1.1)
Total income tax expense					$ 436.5	$ 244.9	$ 169.7

Income Taxes - Schedule Of Deferred Tax Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Share-based compensation expense	$ 79.1	$ 122.2
Expenses deducted in later years for tax purposes	29.7	47.4
Research and other credits	27.5	15.6
Other	10.5	9.8
Gross deferred tax assets	146.8	195.0
Valuation allowance	(29.4)	(17.2)
Deferred tax assets	117.4	177.8
Deferred tax liabilities:
Fixed assets	(26.3)	(25.2)
Intangible assets	(3.6)	(2.3)
Other	(0.2)	(0.2)
Deferred tax liabilities	(30.1)	(27.7)
Net deferred tax assets	$ 87.3	$ 150.1

Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 106.0	$ 92.4	$ 75.5
Increases related to tax positions taken during the current year	21.1	29.9	28.9
Increases related to tax positions taken during a prior year	0.0	0.0	0.3
Decreases related to tax positions taken during a prior year	(46.5)	(0.5)	0.0
Decreases related to settlements with tax authorities	(0.5)	0.0	(11.4)
Decreases related to expiration of statute of limitations	(14.7)	(15.8)	(0.9)
Ending balance	$ 65.4	$ 106.0	$ 92.4

Income Taxes - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended				12 Months Ended
	Jan. 01, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Holiday [Line Items]
Federal statutory tax rate						35.00%	35.00%	35.00%
Provisional income tax expense						$ 317.8	$ 0.0	$ 0.0
Repatriation toll charge payable period						8 years
Provisional estimate of income tax expense related to the 2017 Tax Act		$ 317.8	$ 0.0	$ 0.0	$ 0.0	$ 47.6
Excess tax benefits associated with employee equity plans		19.9	$ 19.7	$ 30.6	$ 32.6	$ 102.8	0.0	0.0
Excess tax benefits related to share-based compensation arrangements, percent reduction						9.40%
Income Tax Holiday, Termination Period						5 years
Valuation allowance		29.4				$ 29.4	17.2
Unrecognized tax benefits, period increase (decrease)						40.6
Total gross unrecognized tax benefits		65.4				65.4	106.0	92.4	$ 75.5
Interest and penalties related to unrecognized tax benefits accrued		$ 1.8				1.8	$ 3.7	$ 2.9
Swiss Federal Tax Administration (FTA)
Income Tax Holiday [Line Items]
Tax benefit from tax holiday						$ 10.9
Tax benefit from tax holiday (in dollars per share)						$ 0.09
Scenario, forecast
Income Tax Holiday [Line Items]
Federal statutory tax rate	21.00%
Pro forma
Income Tax Holiday [Line Items]
Estimated cumulative undistributed foreign earnings						$ 1,873.8
Provisional estimate of income tax expense related to repatriation toll						$ 270.2

Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net income	$ (38.8)	$ 297.5	$ 221.5	$ 179.8	$ 204.0	$ 211.0	$ 184.5	$ 136.4	$ 660.0	$ 735.9	$ 588.8
Weighted-average shares outstanding basic (shares)									111.7	114.9	111.3
Basic net income per share (usd per share)	$ (0.35)	$ 2.66	$ 2.00	$ 1.61	$ 1.75	$ 1.82	$ 1.61	$ 1.21	$ 5.91	$ 6.40	$ 5.29
Weighted-average shares outstanding basic (shares)									111.7	114.9	111.3
Add: Dilutive potential shares									4.6	3.0	2.4
Weighted-average shares used in computing diluted net income per share (shares)									116.3	117.9	113.7
Diluted net income per share (usd per share)	$ (0.35)	$ 2.55	$ 1.92	$ 1.56	$ 1.71	$ 1.77	$ 1.57	$ 1.18	$ 5.67	$ 6.24	$ 5.18

Net Income Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Employee stock options excluded from computation of diluted net income per share	0.2	0.6	5.0

Employee Benefit Plans - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017 USD ($)
Retirement Benefits [Abstract]
Maximum rate of employees' contribution to 401(k) plan	100.00%
Employer match percentage	200.00%
Employer matching contributions	$ 1,500

Selected Quarterly Data - Schedule Of Selected Quarterly Data (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Selected Quarterly Financial Information [Abstract]
Revenue	$ 892.4	$ 806.1	$ 756.2	$ 674.2	$ 756.9	$ 682.9	$ 670.1	$ 594.5	$ 3,128.9	$ 2,704.4	$ 2,384.4
Gross profit	633.3	566.8	527.9	466.1	527.2	487.0	470.9	405.0	2,194.1	1,890.1	1,577.9
Net income	$ (38.8)	$ 297.5	$ 221.5	$ 179.8	$ 204.0	$ 211.0	$ 184.5	$ 136.4	$ 660.0	$ 735.9	$ 588.8
Basic net income per share (usd per share)	$ (0.35)	$ 2.66	$ 2.00	$ 1.61	$ 1.75	$ 1.82	$ 1.61	$ 1.21	$ 5.91	$ 6.40	$ 5.29
Diluted net income per share (usd per share)	$ (0.35)	$ 2.55	$ 1.92	$ 1.56	$ 1.71	$ 1.77	$ 1.57	$ 1.18	$ 5.67	$ 6.24	$ 5.18
Income tax (expense) related to the 2017 Tax Act	$ (317.8)	$ 0.0	$ 0.0	$ 0.0					$ (47.6)
Excess tax benefits related to share-based compensation arrangements	19.9	19.7	30.6	32.6					$ 102.8	$ 0.0	$ 0.0
Certain one-time tax benefits	0.0	68.4	0.0	0.0
Pre-tax medical device excise tax refund benefit					$ 0.0	$ 7.1	$ 0.0	$ 0.0
Audit settlement and expiration of the statutes of limitations in multiple jurisdictions					0.0	15.8	0.0	0.0
Includes pre-tax litigation (charges)	$ 1.2	$ (9.7)	$ 4.5	$ (21.3)	$ (5.5)	$ 0.0	$ (4.4)	$ (2.2)

Valuation And Qualifying Accounts (Detail) - Allowance for doubtful accounts, loan credit losses, and sales returns - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 10.8	$ 9.4	$ 5.5
Additions	36.1	24.6	22.3
Deductions	(32.3)	(23.2)	(18.4)
Balance at End of Year	$ 14.6	$ 10.8	$ 9.4